ISO3,Type,Country/Region,UNICEF Region,Indicator,Data source,Year,Value,Lower,Upper
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,48.0,37.3,57.5
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,58.1,45.2,69.6
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,68.3,53.2,81.9
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,74.1,57.7,88.8
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,79.1,61.6,94.8
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,80.5,62.7,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,79.5,61.9,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,80.7,62.8,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,82.3,64.1,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,84.0,65.3,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,83.1,64.7,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,82.9,64.5,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,81.6,63.5,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,48.0,40.0,61.6
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,58.1,48.5,74.6
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,68.3,57.0,87.8
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,74.1,61.9,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,79.1,66.0,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,80.5,67.2,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,79.5,66.4,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,80.7,67.3,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,82.3,68.7,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,84.0,70.1,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,83.1,69.3,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,82.9,69.2,95.0
03M49WLD,Region,Global,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,81.6,68.1,95.0
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,663000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,800000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,946000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,1030000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,1099000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,1112000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,1087000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,1093000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,1100000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,1102000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,1067000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,1039000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,990000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,663000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,800000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,946000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,1030000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,1099000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,1112000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,1087000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,1093000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,1100000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,1102000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,1067000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,1039000.0,,
03M49WLD,Region,Global,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,990000.0,,
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,1.5,1.0,6.0
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,1.0,1.0,3.9
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,1.0,1.0,1.9
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,2.4,1.0,9.4
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,3.8,1.5,14.5
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,3.3,1.3,12.4
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,3.8,1.4,13.7
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,8.6,3.3,30.5
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,8.7,3.4,30.6
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,11.8,4.8,46.1
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,12.6,4.7,50.4
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,18.6,7.3,75.7
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,15.1,5.5,62.8
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,1.5,1.0,3.8
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,1.0,1.0,2.6
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,1.0,1.0,1.4
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,2.4,1.0,6.7
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,3.8,1.0,10.1
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,3.3,1.0,8.8
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,3.8,1.1,10.3
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,8.6,2.4,22.0
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,8.7,2.5,22.0
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,11.8,3.0,28.9
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,12.6,3.2,33.8
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,18.6,4.6,47.5
AFG,Country,Afghanistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,15.1,3.6,41.3
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,10.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,10.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,10.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,10.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,20.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,20.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,20.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,30.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,40.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,30.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,0.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,0.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,0.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,10.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,10.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,10.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,10.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,20.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,20.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,20.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,30.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,40.0,,
AFG,Country,Afghanistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,30.0,,
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,14.2,11.2,17.2
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,9.7,8.0,11.9
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,11.7,9.6,14.2
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,20.4,16.6,25.2
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,31.4,25.7,37.8
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,29.8,24.5,36.1
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,27.3,22.3,32.7
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,26.0,21.2,31.5
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,36.1,29.3,43.5
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,57.7,46.9,69.4
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,65.5,51.6,80.0
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,74.9,61.1,91.9
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,79.5,63.2,95.0
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,14.2,11.7,17.8
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,9.7,7.9,11.9
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,11.7,9.6,14.2
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,20.4,16.6,25.2
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,31.4,26.1,38.4
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,29.8,24.6,36.1
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,27.3,22.8,33.4
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,26.0,21.4,31.8
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,36.1,29.9,44.5
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,57.7,47.9,70.9
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,65.5,53.7,83.2
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,74.9,61.0,91.8
AGO,Country,Angola,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,79.5,66.2,95.0
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,3700.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,2600.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,3200.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,5700.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,8800.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,8400.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,7600.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,7100.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,9600.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,15000.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,16700.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,18700.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,19400.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,3700.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,2600.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,3200.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,5700.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,8800.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,8400.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,7600.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,7100.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,9600.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,15000.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,16700.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,18700.0,,
AGO,Country,Angola,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,19400.0,,
ARE,Country,United Arab Emirates,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
ARE,Country,United Arab Emirates,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
ARE,Country,United Arab Emirates,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
ARE,Country,United Arab Emirates,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,0.0,,
ARE,Country,United Arab Emirates,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,0.0,,
ARE,Country,United Arab Emirates,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,0.0,,
ARE,Country,United Arab Emirates,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,0.0,,
ARE,Country,United Arab Emirates,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,0.0,,
ARE,Country,United Arab Emirates,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,0.0,,
ARE,Country,United Arab Emirates,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,0.0,,
ARE,Country,United Arab Emirates,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,0.0,,
ARE,Country,United Arab Emirates,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,0.0,,
ARE,Country,United Arab Emirates,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,0.0,,
ARM,Country,Armenia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,20.0,,
ARM,Country,Armenia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,20.0,,
ARM,Country,Armenia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,10.0,,
ARM,Country,Armenia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,20.0,,
ARM,Country,Armenia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,30.0,,
ARM,Country,Armenia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,30.0,,
ARM,Country,Armenia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,40.0,,
ARM,Country,Armenia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,30.0,,
ARM,Country,Armenia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,50.0,,
ARM,Country,Armenia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,50.0,,
ARM,Country,Armenia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,50.0,,
ARM,Country,Armenia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,50.0,,
ARM,Country,Armenia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,50.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,8.7,6.9,11.0
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,15.2,11.5,19.4
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,20.0,15.8,25.6
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,30.7,24.2,38.0
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,45.1,35.4,57.0
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,55.4,43.9,69.2
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,75.3,61.5,92.3
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,84.8,67.6,95.0
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,70.9,58.3,87.0
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,94.3,78.2,95.0
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,79.7,67.6,95.0
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,67.1,54.4,79.0
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,61.5,48.9,75.7
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,8.7,6.9,11.0
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,15.2,11.9,20.0
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,20.0,15.6,25.3
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,30.7,24.8,38.9
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,45.1,35.7,57.5
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,55.4,44.4,70.0
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,75.3,61.4,92.1
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,84.8,68.4,95.0
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,70.9,57.7,86.2
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,94.3,79.0,95.0
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,79.7,63.6,94.0
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,67.1,57.0,82.8
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,61.5,50.0,77.4
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,10.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,20.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,20.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,40.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,50.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,60.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,70.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,70.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,60.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,80.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,60.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,50.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,50.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,10.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,20.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,20.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,40.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,50.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,60.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,70.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,70.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,60.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,80.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,60.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,50.0,,
AZE,Country,Azerbaijan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,50.0,,
BDI,Country,Burundi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,79.2,95.0
BDI,Country,Burundi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,77.6,95.0
BDI,Country,Burundi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,85.1,68.4,95.0
BDI,Country,Burundi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,82.7,95.0
BDI,Country,Burundi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,80.0,95.0
BDI,Country,Burundi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,85.1,72.4,95.0
BDI,Country,Burundi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,4800.0,,
BDI,Country,Burundi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,4500.0,,
BDI,Country,Burundi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,3800.0,,
BDI,Country,Burundi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,4800.0,,
BDI,Country,Burundi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,4500.0,,
BDI,Country,Burundi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,3800.0,,
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,12.9,10.3,15.8
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,16.8,13.2,20.4
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,19.2,15.1,23.3
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,18.0,13.8,21.6
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,30.4,23.3,37.0
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,65.6,50.9,78.3
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,73.2,56.2,88.1
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,65.3,49.4,79.6
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,72.7,54.5,86.9
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,87.5,65.2,95.0
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,94.5,70.1,95.0
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,85.7,63.4,95.0
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,93.6,68.4,95.0
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,12.9,10.6,16.3
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,16.8,13.9,21.6
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,19.2,15.9,24.5
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,18.0,15.0,23.5
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,30.4,25.0,39.7
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,65.6,54.9,84.5
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,73.2,60.9,95.0
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,65.3,53.5,86.4
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,72.7,60.8,95.0
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,87.5,72.1,95.0
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,94.5,78.0,95.0
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,85.7,71.5,95.0
BEN,Country,Benin,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,93.6,77.0,95.0
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,850.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,1100.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,1300.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,1200.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,2100.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,4500.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,5000.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,4400.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,4800.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,5600.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,5900.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,5200.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,5500.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,850.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,1100.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,1300.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,1200.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,2100.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,4500.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,5000.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,4400.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,4800.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,5600.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,5900.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,5200.0,,
BEN,Country,Benin,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,5500.0,,
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,32.3,25.7,39.6
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,36.6,29.1,45.6
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,39.0,31.2,47.0
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,42.0,33.1,51.7
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,55.5,44.0,67.6
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,40.2,32.3,49.3
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,45.6,36.3,56.1
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,51.5,41.1,63.4
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,57.6,45.9,71.3
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,64.4,50.7,80.6
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,71.7,56.8,89.4
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,79.7,62.7,95.0
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,83.8,65.8,95.0
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,32.3,26.3,40.6
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,36.6,29.4,46.1
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,39.0,32.3,48.7
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,42.0,34.2,53.3
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,55.5,45.5,70.0
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,40.2,32.8,50.1
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,45.6,37.1,57.4
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,51.5,41.9,64.6
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,57.6,46.5,72.2
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,64.4,51.4,81.7
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,71.7,57.6,90.6
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,79.7,64.9,95.0
BFA,Country,Burkina Faso,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,83.8,67.6,95.0
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,2800.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,3100.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,3200.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,3400.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,4300.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,3000.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,3300.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,3500.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,3800.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,4100.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,4300.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,4600.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,4600.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,2800.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,3100.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,3200.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,3400.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,4300.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,3000.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,3300.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,3500.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,3800.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,4100.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,4300.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,4600.0,,
BFA,Country,Burkina Faso,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,4600.0,,
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,5.8,4.8,7.0
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,2.6,2.1,3.0
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,4.4,3.7,5.1
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,4.7,3.9,5.5
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,6.2,5.1,7.2
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,5.0,4.2,5.8
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,5.0,4.3,5.9
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,5.5,4.7,6.5
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,7.7,6.4,8.8
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,6.0,5.2,7.1
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,3.7,3.2,4.3
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,7.7,6.6,9.0
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,4.4,3.7,5.0
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,5.8,4.7,7.0
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,2.6,2.2,3.2
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,4.4,3.7,5.2
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,4.7,4.0,5.7
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,6.2,5.2,7.4
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,5.0,4.3,5.9
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,5.0,4.2,5.9
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,5.5,4.7,6.5
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,7.7,6.7,9.2
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,6.0,5.1,7.0
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,3.7,3.2,4.3
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,7.7,6.6,9.0
BGD,Country,Bangladesh,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,4.4,3.8,5.2
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,20.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,10.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,20.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,20.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,30.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,20.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,20.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,30.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,40.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,30.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,20.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,40.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,20.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,20.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,10.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,20.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,20.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,30.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,20.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,20.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,30.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,40.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,30.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,20.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,40.0,,
BGD,Country,Bangladesh,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,20.0,,
BHR,Country,Bahrain,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
BHR,Country,Bahrain,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
BHR,Country,Bahrain,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
BHR,Country,Bahrain,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,0.0,,
BHR,Country,Bahrain,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,0.0,,
BHR,Country,Bahrain,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,0.0,,
BHR,Country,Bahrain,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,0.0,,
BHR,Country,Bahrain,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,0.0,,
BHR,Country,Bahrain,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,0.0,,
BHR,Country,Bahrain,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,0.0,,
BHR,Country,Bahrain,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,0.0,,
BHR,Country,Bahrain,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,0.0,,
BHR,Country,Bahrain,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,0.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,41.6,37.3,46.1
BHS,Country,Bahamas,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,38.9,34.6,43.5
BHS,Country,Bahamas,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,88.8,79.1,95.0
BHS,Country,Bahamas,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,95.0,89.0,95.0
BHS,Country,Bahamas,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,83.9,74.5,94.8
BHS,Country,Bahamas,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,64.2,57.1,72.2
BHS,Country,Bahamas,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,89.2,78.6,95.0
BHS,Country,Bahamas,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,75.0,65.4,85.0
BHS,Country,Bahamas,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,79.1,68.8,89.8
BHS,Country,Bahamas,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,75.0,65.8,85.7
BHS,Country,Bahamas,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,59.0,51.4,69.2
BHS,Country,Bahamas,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,49.1,41.8,57.1
BHS,Country,Bahamas,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,60.4,51.6,71.1
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,50.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,40.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,90.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,80.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,70.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,50.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,70.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,50.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,50.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,50.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,40.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,30.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,30.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,50.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,40.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,90.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,80.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,70.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,50.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,70.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,50.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,50.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,50.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,40.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,30.0,,
BHS,Country,Bahamas,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,30.0,,
BIH,Country,Bosnia and Herzegovina,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
BIH,Country,Bosnia and Herzegovina,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
BIH,Country,Bosnia and Herzegovina,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
BIH,Country,Bosnia and Herzegovina,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,0.0,,
BIH,Country,Bosnia and Herzegovina,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,0.0,,
BIH,Country,Bosnia and Herzegovina,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,0.0,,
BIH,Country,Bosnia and Herzegovina,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,0.0,,
BIH,Country,Bosnia and Herzegovina,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,0.0,,
BIH,Country,Bosnia and Herzegovina,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,0.0,,
BIH,Country,Bosnia and Herzegovina,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,0.0,,
BIH,Country,Bosnia and Herzegovina,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,0.0,,
BIH,Country,Bosnia and Herzegovina,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,0.0,,
BIH,Country,Bosnia and Herzegovina,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,0.0,,
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,94.6,81.1,95.0
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,95.0,95.0,95.0
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,95.0,84.6,95.0
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,69.7,60.2,79.2
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,78.6,70.7,86.4
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,79.1,70.8,88.5
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,58.5,52.2,65.7
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,67.2,59.8,75.6
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,74.2,65.2,83.2
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,67.8,59.8,77.0
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,72.1,63.9,80.4
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,73.3,66.0,83.1
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,72.9,64.2,81.5
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,94.6,82.8,95.0
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,95.0,95.0,95.0
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,95.0,84.6,95.0
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,69.7,61.3,80.7
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,78.6,71.4,87.3
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,79.1,70.7,88.3
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,58.5,52.1,65.5
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,67.2,59.7,75.4
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,74.2,66.2,84.5
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,67.8,59.7,76.9
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,72.1,64.7,81.5
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,73.3,64.7,81.5
BLZ,Country,Belize,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,72.9,65.2,82.7
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,50.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,90.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,70.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,50.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,60.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,50.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,40.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,40.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,50.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,40.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,40.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,40.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,40.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,50.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,90.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,70.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,50.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,60.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,50.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,40.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,40.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,50.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,40.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,40.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,40.0,,
BLZ,Country,Belize,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,40.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,25.0,21.0,30.8
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,31.6,26.2,39.1
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,46.6,39.1,57.6
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,39.3,32.7,47.9
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,42.1,35.6,50.8
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,51.6,44.1,62.0
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,61.9,52.4,74.4
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,92.9,79.1,95.0
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,80.9,68.7,95.0
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,83.6,71.9,95.0
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,72.7,62.4,86.4
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,82.7,71.0,95.0
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,87.6,74.6,95.0
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,25.0,20.2,29.7
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,31.6,25.5,38.0
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,46.6,37.7,55.6
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,39.3,32.3,47.3
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,42.1,34.9,49.8
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,51.6,43.0,60.4
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,61.9,51.6,73.2
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,92.9,78.4,95.0
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,80.9,68.6,95.0
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,83.6,70.0,95.0
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,72.7,61.2,84.8
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,82.7,70.9,95.0
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,87.6,74.7,95.0
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,130.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,170.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,250.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,210.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,230.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,280.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,350.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,520.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,460.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,480.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,420.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,480.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,510.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,130.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,170.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,250.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,210.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,230.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,280.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,350.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,520.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,460.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,480.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,420.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,480.0,,
BOL,Country,Bolivia (Plurinational State of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,510.0,,
BRB,Country,Barbados,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,20.0,,
BRB,Country,Barbados,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,20.0,,
BRB,Country,Barbados,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,20.0,,
BRB,Country,Barbados,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,20.0,,
BRB,Country,Barbados,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,20.0,,
BRB,Country,Barbados,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,20.0,,
BRB,Country,Barbados,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,20.0,,
BRB,Country,Barbados,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,20.0,,
BRB,Country,Barbados,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,20.0,,
BRB,Country,Barbados,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,20.0,,
BRB,Country,Barbados,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,10.0,,
BRB,Country,Barbados,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,20.0,,
BRB,Country,Barbados,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,20.0,,
BTN,Country,Bhutan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,10.0,,
BTN,Country,Bhutan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,10.0,,
BTN,Country,Bhutan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,10.0,,
BTN,Country,Bhutan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,10.0,,
BTN,Country,Bhutan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,10.0,,
BTN,Country,Bhutan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,20.0,,
BTN,Country,Bhutan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,10.0,,
BTN,Country,Bhutan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,10.0,,
BTN,Country,Bhutan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,10.0,,
BTN,Country,Bhutan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,0.0,,
BTN,Country,Bhutan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,10.0,,
BTN,Country,Bhutan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,10.0,,
BTN,Country,Bhutan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,10.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,70.4,55.4,79.2
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,64.0,51.2,73.1
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,80.5,63.2,91.8
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,82.1,63.9,93.4
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,75.4,59.5,84.6
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,78.8,62.4,90.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,78.4,61.9,88.3
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,88.8,69.5,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,75.2,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,80.5,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,81.9,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,73.1,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,73.4,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,70.4,62.6,89.4
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,64.0,56.1,80.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,80.5,70.6,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,82.1,72.2,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,75.4,67.2,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,78.8,69.1,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,78.4,69.6,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,88.8,78.2,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,86.9,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,93.0,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,94.5,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,84.9,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,85.0,95.0
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,11000.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,9900.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,12300.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,12300.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,11000.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,11100.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,10800.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,11900.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,12500.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,12700.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,12200.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,10200.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,9600.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,11000.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,9900.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,12300.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,12300.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,11000.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,11100.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,10800.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,11900.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,12500.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,12700.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,12200.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,10200.0,,
BWA,Country,Botswana,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,9600.0,,
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,23.7,19.6,28.7
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,30.7,25.7,36.4
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,34.2,28.4,41.4
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,20.1,16.1,24.0
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,34.7,28.2,42.6
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,38.7,31.1,47.8
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,55.0,44.3,69.2
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,40.1,32.4,52.2
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,43.6,33.8,56.7
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,54.2,40.8,73.4
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,47.6,35.5,67.8
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,50.2,37.9,75.9
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,39.0,28.3,62.8
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,23.7,19.6,28.7
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,30.7,26.0,36.8
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,34.2,28.3,41.3
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,20.1,16.8,25.1
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,34.7,28.3,42.7
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,38.7,31.4,48.2
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,55.0,43.7,68.3
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,40.1,30.8,49.6
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,43.6,33.5,56.1
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,54.2,40.0,72.0
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,47.6,33.4,63.8
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,50.2,33.1,66.4
CAF,Country,Central African Republic,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,39.0,24.3,53.8
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,2000.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,2600.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,2700.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,1500.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,2600.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,2700.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,3900.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,2900.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,3200.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,4000.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,3600.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,4000.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,3100.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,2000.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,2600.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,2700.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,1500.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,2600.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,2700.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,3900.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,2900.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,3200.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,4000.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,3600.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,4000.0,,
CAF,Country,Central African Republic,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,3100.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,46.2,38.8,54.7
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,44.4,37.2,52.4
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,58.4,49.9,68.8
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,74.1,62.1,86.9
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,86.4,72.8,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,89.3,76.1,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,87.8,73.7,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,91.7,76.7,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,91.8,76.8,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,86.2,71.4,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,81.7,67.1,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,84.5,69.4,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,79.5,64.7,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,46.2,39.0,55.1
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,44.4,37.7,53.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,58.4,49.5,68.2
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,74.1,63.2,88.4
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,86.4,73.3,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,89.3,75.9,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,87.8,74.6,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,91.7,77.2,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,91.8,77.7,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,86.2,73.5,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,81.7,69.4,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,84.5,70.2,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,79.5,65.9,95.0
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,11600.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,10600.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,13300.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,16000.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,17800.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,17700.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,16900.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,17300.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,16500.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,14900.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,13500.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,13400.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,12000.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,11600.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,10600.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,13300.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,16000.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,17800.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,17700.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,16900.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,17300.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,16500.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,14900.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,13500.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,13400.0,,
CIV,Country,Cte d'Ivoire,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,12000.0,,
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,42.2,34.9,48.0
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,48.6,40.1,55.2
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,57.5,47.4,65.4
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,76.7,60.6,87.2
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,75.6,61.2,85.4
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,91.5,73.3,95.0
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,79.7,64.2,89.5
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,81.3,64.9,91.5
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,78.5,61.5,87.3
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,63.6,50.6,71.6
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,64.9,50.0,73.3
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,70.0,54.1,79.0
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,67.7,51.6,77.1
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,42.2,37.1,51.1
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,48.6,42.8,58.8
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,57.5,50.5,69.7
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,76.7,67.5,95.0
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,75.6,67.0,93.4
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,91.5,81.5,95.0
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,79.7,71.0,95.0
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,81.3,72.3,95.0
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,78.5,70.7,95.0
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,63.6,56.5,80.0
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,64.9,57.5,84.3
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,70.0,62.0,90.6
CMR,Country,Cameroon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,67.7,59.5,88.9
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,13800.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,15400.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,17800.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,23200.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,22300.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,26700.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,23000.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,23100.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,21700.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,17100.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,16800.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,17300.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,16000.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,13800.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,15400.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,17800.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,23200.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,22300.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,26700.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,23000.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,23100.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,21700.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,17100.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,16800.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,17300.0,,
CMR,Country,Cameroon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,16000.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,3.2,2.6,3.9
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,1.0,1.0,1.0
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,2.9,2.3,3.4
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,9.5,7.8,11.5
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,38.4,31.3,46.1
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,53.9,44.5,64.7
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,48.6,39.1,58.1
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,39.7,32.3,47.7
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,51.8,42.5,63.1
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,45.2,36.3,55.4
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,40.7,32.5,50.2
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,37.2,29.5,46.6
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,3.2,2.7,4.0
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,1.0,1.0,1.0
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,2.9,2.4,3.6
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,9.5,7.8,11.7
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,38.4,32.1,47.2
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,53.9,44.8,65.2
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,48.6,40.6,60.4
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,39.7,33.0,48.9
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,51.8,42.5,63.1
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,45.2,36.9,56.3
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,40.7,33.0,50.9
COD,Country,Democratic Republic of the Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,37.2,29.7,46.9
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,980.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,850.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,2800.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,11100.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,15400.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,13900.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,11400.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,14500.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,12500.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,11300.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,10300.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,980.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,0.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,850.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,2800.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,11100.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,15400.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,13900.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,11400.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,14500.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,12500.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,11300.0,,
COD,Country,Democratic Republic of the Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,10300.0,,
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,10.9,8.6,13.3
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,24.1,19.8,30.0
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,18.9,15.1,22.7
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,24.3,19.1,29.2
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,19.5,15.4,24.1
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,18.4,14.5,22.4
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,10.7,8.0,13.4
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,10.8,7.9,13.8
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,7.2,5.2,9.3
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,7.3,4.9,9.9
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,12.0,8.1,17.0
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,21.0,13.8,31.2
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,19.5,12.9,29.5
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,10.9,8.8,13.7
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,24.1,19.4,29.5
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,18.9,15.8,23.7
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,24.3,20.2,30.9
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,19.5,15.8,24.8
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,18.4,15.1,23.3
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,10.7,8.6,14.3
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,10.8,8.5,14.7
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,7.2,5.6,10.0
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,7.3,5.4,10.7
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,12.0,8.5,17.9
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,21.0,14.1,31.7
COG,Country,Congo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,19.5,13.0,29.7
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,620.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,1400.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,1100.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,1500.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,1200.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,1100.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,670.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,700.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,480.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,500.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,870.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,1600.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,1500.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,620.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,1400.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,1100.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,1500.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,1200.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,1100.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,670.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,700.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,480.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,500.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,870.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,1600.0,,
COG,Country,Congo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,1500.0,,
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,42.2,34.4,50.8
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,49.8,41.6,60.2
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,51.0,43.0,60.4
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,53.9,45.8,64.2
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,60.7,51.5,72.2
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,51.9,44.1,62.3
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,55.4,46.0,65.6
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,57.2,47.7,68.1
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,55.7,46.5,67.1
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,56.3,45.9,68.8
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,55.0,44.1,69.1
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,42.2,35.1,51.8
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,49.8,41.1,59.5
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,51.0,43.0,60.4
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,53.9,45.3,63.5
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,60.7,51.1,71.6
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,51.9,43.3,61.1
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,55.4,46.9,66.8
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,57.2,48.0,68.5
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,55.7,46.3,66.8
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,56.3,46.1,69.1
COL,Country,Colombia,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,55.0,43.9,68.8
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,620.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,730.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,740.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,780.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,860.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,740.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,770.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,780.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,740.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,750.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,740.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,620.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,730.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,740.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,780.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,860.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,740.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,770.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,780.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,740.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,750.0,,
COL,Country,Colombia,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,740.0,,
COM,Country,Comoros,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,10.0,,
COM,Country,Comoros,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
COM,Country,Comoros,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
COM,Country,Comoros,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,0.0,,
COM,Country,Comoros,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,0.0,,
COM,Country,Comoros,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,0.0,,
COM,Country,Comoros,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,10.0,,
COM,Country,Comoros,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,10.0,,
COM,Country,Comoros,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,10.0,,
COM,Country,Comoros,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,10.0,,
COM,Country,Comoros,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,0.0,,
COM,Country,Comoros,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,0.0,,
COM,Country,Comoros,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,10.0,,
CPV,Country,Cabo Verde,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,95.0,95.0,95.0
CPV,Country,Cabo Verde,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,95.0,95.0,95.0
CPV,Country,Cabo Verde,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,95.0,95.0
CPV,Country,Cabo Verde,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,95.0,95.0
CPV,Country,Cabo Verde,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,63.5,47.4,79.6
CPV,Country,Cabo Verde,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,71.1,95.0
CPV,Country,Cabo Verde,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,93.7,69.9,95.0
CPV,Country,Cabo Verde,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,95.0,95.0,95.0
CPV,Country,Cabo Verde,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,95.0,95.0,95.0
CPV,Country,Cabo Verde,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,95.0,95.0
CPV,Country,Cabo Verde,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,95.0,95.0
CPV,Country,Cabo Verde,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,63.5,50.6,85.1
CPV,Country,Cabo Verde,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,75.0,95.0
CPV,Country,Cabo Verde,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,93.7,72.8,95.0
CPV,Country,Cabo Verde,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,90.0,,
CPV,Country,Cabo Verde,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,80.0,,
CPV,Country,Cabo Verde,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,90.0,,
CPV,Country,Cabo Verde,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,80.0,,
CPV,Country,Cabo Verde,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,40.0,,
CPV,Country,Cabo Verde,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,60.0,,
CPV,Country,Cabo Verde,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,60.0,,
CPV,Country,Cabo Verde,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,90.0,,
CPV,Country,Cabo Verde,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,80.0,,
CPV,Country,Cabo Verde,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,90.0,,
CPV,Country,Cabo Verde,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,80.0,,
CPV,Country,Cabo Verde,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,40.0,,
CPV,Country,Cabo Verde,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,60.0,,
CPV,Country,Cabo Verde,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,60.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,1.0,1.0,1.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,1.0,1.0,1.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,1.0,1.0,1.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,42.7,37.9,46.5
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,52.8,48.1,58.1
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,92.1,82.8,95.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,94.4,84.8,95.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,95.0,95.0,95.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,95.0,95.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,95.0,95.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,92.4,83.0,95.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,95.0,95.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,1.0,1.0,1.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,1.0,1.0,1.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,1.0,1.0,1.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,42.7,39.2,48.1
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,52.8,48.0,58.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,92.1,84.5,95.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,94.4,84.8,95.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,95.0,95.0,95.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,95.0,95.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,95.0,95.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,92.4,82.0,95.0
CRI,Country,Costa Rica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,95.0,95.0
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,40.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,50.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,80.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,80.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,100.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,100.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,120.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,70.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,90.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,0.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,0.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,0.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,40.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,50.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,80.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,80.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,100.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,100.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,120.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,70.0,,
CRI,Country,Costa Rica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,90.0,,
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,54.9,49.5,61.2
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,87.6,78.6,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,95.0,89.4,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,72.5,63.7,80.3
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,63.0,56.9,69.1
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,85.8,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,88.3,80.6,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,91.0,81.6,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,94.8,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,95.0,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,95.0,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,95.0,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,95.0,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,54.9,49.3,60.9
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,87.6,78.9,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,95.0,89.1,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,72.5,65.5,82.4
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,63.0,57.4,69.8
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,87.2,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,88.3,79.4,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,91.0,82.5,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,95.0,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,95.0,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,95.0,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,95.0,95.0
CUB,Country,Cuba,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,95.0,95.0
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,70.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,120.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,140.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,110.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,100.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,160.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,140.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,150.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,180.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,190.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,200.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,180.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,190.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,70.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,120.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,140.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,110.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,100.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,160.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,140.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,150.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,180.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,190.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,200.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,180.0,,
CUB,Country,Cuba,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,190.0,,
DJI,Country,Djibouti,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,40.0,,
DJI,Country,Djibouti,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,50.0,,
DJI,Country,Djibouti,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,40.0,,
DJI,Country,Djibouti,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,30.0,,
DJI,Country,Djibouti,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,60.0,,
DJI,Country,Djibouti,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,80.0,,
DJI,Country,Djibouti,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,80.0,,
DJI,Country,Djibouti,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,50.0,,
DJI,Country,Djibouti,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,60.0,,
DJI,Country,Djibouti,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,40.0,,
DJI,Country,Djibouti,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,50.0,,
DJI,Country,Djibouti,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,50.0,,
DJI,Country,Djibouti,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,20.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,32.7,28.0,38.1
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,47.0,40.5,54.7
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,58.6,48.6,66.8
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,44.7,36.9,52.3
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,50.7,42.4,60.3
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,43.3,35.6,51.7
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,45.3,35.5,54.6
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,40.8,32.1,49.6
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,38.7,29.7,47.6
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,33.2,24.9,40.0
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,26.6,20.4,32.8
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,44.4,33.5,54.8
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,58.3,43.7,70.8
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,32.7,28.1,38.2
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,47.0,40.3,54.5
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,58.6,51.4,70.7
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,44.7,38.2,54.1
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,50.7,42.7,60.7
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,43.3,36.2,52.7
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,45.3,37.5,57.7
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,40.8,33.6,52.0
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,38.7,31.5,50.6
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,33.2,27.5,44.2
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,26.6,21.6,34.8
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,44.4,35.9,58.8
DOM,Country,Dominican Republic,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,58.3,48.0,77.8
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,770.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,1100.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,1300.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,970.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,1100.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,890.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,910.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,810.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,770.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,650.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,520.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,880.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,1200.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,770.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,1100.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,1300.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,970.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,1100.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,890.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,910.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,810.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,770.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,650.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,520.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,880.0,,
DOM,Country,Dominican Republic,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,1200.0,,
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,37.4,34.2,40.8
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,34.6,31.8,37.7
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,28.5,26.1,30.9
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,42.3,39.1,45.1
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,20.8,19.4,22.3
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,18.4,17.2,19.7
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,30.8,28.8,33.0
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,36.6,34.3,39.2
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,42.6,39.8,46.0
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,45.4,41.8,48.8
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,31.5,28.8,34.0
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,22.8,21.0,25.0
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,25.5,23.0,27.7
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,37.4,34.3,40.8
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,34.6,31.8,37.6
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,28.5,26.4,31.2
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,42.3,39.6,45.8
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,20.8,19.4,22.3
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,18.4,17.2,19.6
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,30.8,28.7,33.0
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,36.6,34.2,39.1
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,42.6,39.4,45.5
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,45.4,42.2,49.2
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,31.5,29.3,34.5
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,22.8,20.9,24.8
DZA,Country,Algeria,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,25.5,23.5,28.3
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,120.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,130.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,120.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,200.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,110.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,110.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,210.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,260.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,320.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,360.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,260.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,190.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,210.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,120.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,130.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,120.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,200.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,110.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,110.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,210.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,260.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,320.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,360.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,260.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,190.0,,
DZA,Country,Algeria,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,210.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,39.4,34.0,46.5
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,41.8,36.0,48.5
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,45.2,39.3,52.9
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,46.0,40.4,53.1
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,47.4,42.1,54.5
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,48.7,43.5,55.4
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,50.1,44.4,56.5
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,50.6,44.8,57.3
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,51.5,45.6,58.5
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,79.4,70.4,89.3
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,61.4,54.3,69.8
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,76.3,66.8,86.9
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,89.7,77.2,95.0
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,39.4,33.5,45.8
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,41.8,36.0,48.7
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,45.2,38.6,51.9
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,46.0,39.8,52.2
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,47.4,41.3,53.4
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,48.7,42.8,54.5
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,50.1,44.4,56.5
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,50.6,44.6,57.0
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,51.5,45.3,58.0
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,79.4,70.5,89.5
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,61.4,54.0,69.4
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,76.3,66.9,87.1
ECU,Country,Ecuador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,89.7,78.0,95.0
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,270.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,290.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,310.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,320.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,330.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,350.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,360.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,360.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,370.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,580.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,450.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,550.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,630.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,270.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,290.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,310.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,320.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,330.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,350.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,360.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,360.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,370.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,580.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,450.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,550.0,,
ECU,Country,Ecuador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,630.0,,
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,4.4,3.8,5.1
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,2.5,2.2,2.8
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,2.8,2.5,3.3
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,10.7,9.2,12.1
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,8.2,7.3,9.3
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,7.6,6.8,8.6
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,12.4,11.3,14.1
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,12.1,11.0,13.5
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,12.5,11.3,13.9
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,14.3,12.9,16.0
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,16.0,14.2,18.0
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,26.9,24.1,30.8
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,27.5,24.5,31.3
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,4.4,3.8,5.0
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,2.5,2.1,2.8
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,2.8,2.4,3.2
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,10.7,9.4,12.4
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,8.2,7.2,9.2
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,7.6,6.8,8.6
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,12.4,10.9,13.6
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,12.1,10.8,13.4
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,12.5,11.2,13.8
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,14.3,12.7,15.8
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,16.0,14.2,18.0
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,26.9,23.5,30.0
EGY,Country,Egypt,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,27.5,24.1,30.9
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,10.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,10.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,10.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,40.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,30.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,30.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,50.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,50.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,60.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,70.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,80.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,140.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,150.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,10.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,10.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,10.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,40.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,30.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,30.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,50.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,50.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,60.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,70.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,80.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,140.0,,
EGY,Country,Egypt,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,150.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,37.2,25.1,51.7
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,59.5,39.9,80.4
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,95.0,70.1,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,95.0,72.7,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,95.0,85.8,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,71.7,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,80.4,54.4,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,90.8,60.8,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,70.5,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,89.4,60.4,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,69.1,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,84.3,56.8,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,93.3,62.8,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,37.2,26.8,55.1
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,59.5,44.0,88.8
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,95.0,75.0,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,95.0,80.7,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,95.0,91.4,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,77.1,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,80.4,58.2,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,90.8,65.8,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,76.2,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,89.4,63.4,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,71.6,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,84.3,59.8,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,93.3,65.5,95.0
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,150.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,220.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,360.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,360.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,390.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,300.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,210.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,220.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,230.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,190.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,190.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,150.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,150.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,150.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,220.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,360.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,360.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,390.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,300.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,210.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,220.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,230.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,190.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,190.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,150.0,,
ERI,Country,Eritrea,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,150.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,24.3,17.7,33.3
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,37.0,26.9,50.7
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,58.6,42.6,80.2
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,69.1,50.2,94.6
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,70.6,51.3,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,77.4,56.2,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,69.8,50.7,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,66.9,48.6,91.6
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,77.8,56.4,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,82.9,60.2,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,92.5,67.2,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,80.1,58.1,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,85.9,62.4,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,24.3,17.8,33.5
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,37.0,27.1,51.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,58.6,42.8,80.8
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,69.1,50.5,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,70.6,51.6,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,77.4,56.6,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,69.8,51.0,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,66.9,48.9,92.2
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,77.8,56.8,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,82.9,60.6,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,92.5,67.6,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,80.1,58.5,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,85.9,62.8,95.0
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,6800.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,10100.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,15700.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,18000.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,17800.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,19000.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,16600.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,15000.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,16400.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,16400.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,17200.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,13900.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,14200.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,6800.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,10100.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,15700.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,18000.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,17800.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,19000.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,16600.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,15000.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,16400.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,16400.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,17200.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,13900.0,,
ETH,Country,Ethiopia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,14200.0,,
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,36.0,24.5,66.2
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,63.0,42.0,95.0
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,64.5,45.8,95.0
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,32.4,22.8,59.0
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,44.7,31.8,82.4
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,33.3,23.0,60.3
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,54.3,36.6,95.0
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,78.0,51.5,95.0
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,69.6,42.3,95.0
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,35.5,21.7,73.3
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,48.5,28.5,95.0
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,40.8,23.6,82.7
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,35.7,20.4,72.3
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,36.0,19.6,52.9
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,63.0,35.4,94.4
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,64.5,35.1,90.9
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,32.4,17.7,45.8
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,44.7,24.3,63.0
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,33.3,18.4,48.3
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,54.3,28.1,80.6
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,78.0,39.8,95.0
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,69.6,33.9,95.0
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,35.5,17.2,57.9
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,48.5,24.3,82.5
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,40.8,20.1,70.5
FJI,Country,Fiji,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,35.7,17.6,62.5
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,10.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,20.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,20.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,10.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,20.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,10.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,30.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,40.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,40.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,20.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,30.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,30.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,30.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,10.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,20.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,20.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,10.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,20.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,10.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,30.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,40.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,40.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,20.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,30.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,30.0,,
FJI,Country,Fiji,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,30.0,,
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,19.9,15.7,24.7
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,26.3,20.7,32.7
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,33.9,27.2,42.1
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,44.3,35.2,55.8
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,45.8,35.7,58.7
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,56.2,43.3,71.0
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,72.0,56.4,94.0
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,68.5,52.4,90.0
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,75.6,57.4,95.0
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,81.4,61.3,95.0
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,73.7,95.0
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,77.1,57.2,95.0
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,81.7,58.0,95.0
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,19.9,16.1,25.2
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,26.3,21.1,33.4
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,33.9,27.4,42.4
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,44.3,35.2,55.8
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,45.8,35.8,58.8
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,56.2,44.4,72.9
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,72.0,55.1,91.8
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,68.5,52.0,89.4
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,75.6,56.8,95.0
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,81.4,59.1,95.0
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,70.3,95.0
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,77.1,53.6,95.0
GAB,Country,Gabon,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,81.7,57.5,95.0
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,640.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,840.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,1100.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,1400.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,1400.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,1700.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,2000.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,1800.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,1900.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,1900.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,2300.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,1700.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,1800.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,640.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,840.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,1100.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,1400.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,1400.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,1700.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,2000.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,1800.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,1900.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,1900.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,2300.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,1700.0,,
GAB,Country,Gabon,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,1800.0,,
GEO,Country,Georgia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,30.0,,
GEO,Country,Georgia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,30.0,,
GEO,Country,Georgia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,20.0,,
GEO,Country,Georgia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,40.0,,
GEO,Country,Georgia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,60.0,,
GEO,Country,Georgia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,60.0,,
GEO,Country,Georgia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,50.0,,
GEO,Country,Georgia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,50.0,,
GEO,Country,Georgia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,30.0,,
GEO,Country,Georgia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,40.0,,
GEO,Country,Georgia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,40.0,,
GEO,Country,Georgia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,50.0,,
GEO,Country,Georgia,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,40.0,,
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,34.2,28.4,40.3
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,46.8,39.1,55.8
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,51.4,43.2,60.9
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,41.7,34.6,49.6
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,48.4,40.4,56.9
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,45.3,38.3,53.3
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,57.4,48.3,67.4
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,65.2,54.4,77.3
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,68.9,58.2,81.7
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,70.9,58.4,83.1
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,76.5,62.4,91.1
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,93.3,77.5,95.0
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,84.8,69.4,95.0
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,34.2,29.0,41.1
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,46.8,39.3,56.1
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,51.4,43.4,61.2
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,41.7,35.1,50.3
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,48.4,41.2,58.0
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,45.3,38.5,53.6
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,57.4,48.9,68.3
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,65.2,55.0,78.1
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,68.9,58.1,81.5
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,70.9,60.4,86.0
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,76.5,64.3,94.0
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,93.3,78.4,95.0
GHA,Country,Ghana,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,84.8,69.9,95.0
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,5800.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,8100.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,9000.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,7300.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,8300.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,7800.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,9700.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,10600.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,11400.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,11700.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,12700.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,15600.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,14100.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,5800.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,8100.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,9000.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,7300.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,8300.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,7800.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,9700.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,10600.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,11400.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,11700.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,12700.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,15600.0,,
GHA,Country,Ghana,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,14100.0,,
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,19.0,15.0,22.3
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,33.7,27.3,39.5
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,34.0,27.9,40.5
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,67.3,54.0,80.3
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,1.0,1.0,1.0
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,1.0,1.0,1.0
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,1.0,1.0,1.0
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,1.0,1.0,1.0
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,1.0,1.0,1.0
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,52.7,41.8,63.1
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,58.0,46.5,69.5
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,61.1,47.7,74.4
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,56.0,43.9,67.5
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,19.0,16.2,24.0
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,33.7,28.6,41.5
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,34.0,28.6,41.6
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,67.3,56.5,83.9
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,1.0,1.0,1.0
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,1.0,1.0,1.0
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,1.0,1.0,1.0
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,1.0,1.0,1.0
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,1.0,1.0,1.0
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,52.7,44.0,66.4
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,58.0,48.5,72.4
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,61.1,50.2,78.3
GIN,Country,Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,56.0,46.4,71.3
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,1100.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,1900.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,2000.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,3900.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,0.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,0.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,0.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,0.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,0.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,3000.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,3400.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,3500.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,3200.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,1100.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,1900.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,2000.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,3900.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,0.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,0.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,0.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,0.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,0.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,3000.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,3400.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,3500.0,,
GIN,Country,Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,3200.0,,
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,41.6,31.7,53.5
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,55.8,43.0,71.7
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,47.1,36.2,60.5
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,48.8,37.3,62.2
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,48.8,38.3,63.2
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,59.9,47.0,76.6
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,52.5,39.1,67.0
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,52.0,39.3,67.3
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,50.7,39.4,65.3
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,47.1,35.3,60.3
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,45.4,34.8,58.9
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,60.6,45.3,79.5
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,59.0,43.3,75.9
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,41.6,32.3,54.5
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,55.8,43.4,72.4
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,47.1,36.6,61.1
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,48.8,38.3,63.8
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,48.8,37.7,62.2
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,59.9,46.9,76.5
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,52.5,41.1,70.4
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,52.0,40.2,68.9
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,50.7,39.3,65.2
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,47.1,36.8,62.9
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,45.4,34.9,59.2
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,60.6,46.2,81.1
GMB,Country,Gambia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,59.0,45.8,80.2
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,600.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,820.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,700.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,730.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,720.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,870.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,750.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,730.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,700.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,620.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,580.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,740.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,690.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,600.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,820.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,700.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,730.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,720.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,870.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,750.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,730.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,700.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,620.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,580.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,740.0,,
GMB,Country,Gambia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,690.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,16.8,14.0,19.7
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,24.3,20.6,28.7
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,37.2,31.6,43.1
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,61.0,51.5,70.2
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,95.0,83.9,95.0
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,88.5,72.6,95.0
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,86.6,72.6,95.0
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,86.7,70.5,95.0
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,64.7,52.7,75.4
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,78.7,65.3,90.6
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,80.4,65.5,94.9
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,59.6,48.9,70.5
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,60.3,49.0,71.3
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,16.8,14.3,20.2
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,24.3,20.7,28.8
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,37.2,32.1,43.8
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,61.0,53.0,72.2
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,95.0,88.9,95.0
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,88.5,76.2,95.0
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,86.6,74.8,95.0
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,86.7,74.3,95.0
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,64.7,55.5,79.4
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,78.7,68.4,94.9
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,80.4,68.1,95.0
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,59.6,50.5,72.8
GNB,Country,Guinea-Bissau,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,60.3,51.0,74.3
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,340.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,490.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,740.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,1200.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,1900.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,1600.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,1500.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,1400.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,1000.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,1200.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,1200.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,820.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,810.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,340.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,490.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,740.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,1200.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,1900.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,1600.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,1500.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,1400.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,1000.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,1200.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,1200.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,820.0,,
GNB,Country,Guinea-Bissau,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,810.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,13.0,10.2,16.1
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,6.9,5.5,8.5
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,11.3,8.8,13.8
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,49.3,38.2,61.3
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,48.1,38.3,60.4
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,38.0,30.2,47.7
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,59.0,45.0,73.5
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,54.3,41.8,70.5
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,44.5,34.3,57.8
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,44.3,33.0,57.8
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,32.2,24.2,42.0
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,42.4,31.7,57.5
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,47.3,34.2,64.5
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,13.0,10.6,16.7
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,6.9,5.6,8.8
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,11.3,9.2,14.4
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,49.3,39.7,63.6
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,48.1,38.4,60.4
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,38.0,30.3,47.9
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,59.0,47.4,77.4
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,54.3,41.9,70.6
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,44.5,34.2,57.7
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,44.3,34.0,59.6
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,32.2,24.6,42.7
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,42.4,31.3,56.7
GNQ,Country,Equatorial Guinea,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,47.3,34.6,65.4
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,260.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,150.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,250.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,1200.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,1200.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,990.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,1600.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,1500.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,1300.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,1300.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,960.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,1300.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,1400.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,260.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,150.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,250.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,1200.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,1200.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,990.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,1600.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,1500.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,1300.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,1300.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,960.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,1300.0,,
GNQ,Country,Equatorial Guinea,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,1400.0,,
GRD,Country,Grenada,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
GRD,Country,Grenada,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,10.0,,
GRD,Country,Grenada,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,10.0,,
GRD,Country,Grenada,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,10.0,,
GRD,Country,Grenada,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,0.0,,
GRD,Country,Grenada,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,10.0,,
GRD,Country,Grenada,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,10.0,,
GRD,Country,Grenada,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,0.0,,
GRD,Country,Grenada,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,10.0,,
GRD,Country,Grenada,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,0.0,,
GRD,Country,Grenada,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,0.0,,
GRD,Country,Grenada,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,10.0,,
GRD,Country,Grenada,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,0.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,23.7,20.6,28.1
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,31.4,27.4,36.0
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,23.1,20.3,26.6
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,36.5,32.6,41.4
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,32.5,29.3,37.2
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,20.2,17.9,23.1
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,25.6,22.6,29.1
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,27.3,23.9,30.9
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,33.6,29.7,38.5
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,33.9,29.8,38.3
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,34.6,30.1,39.0
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,38.7,33.6,44.4
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,44.3,38.7,51.1
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,23.7,19.9,27.2
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,31.4,27.5,36.0
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,23.1,20.0,26.3
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,36.5,32.2,40.9
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,32.5,28.4,36.1
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,20.2,17.6,22.7
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,25.6,22.4,28.9
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,27.3,24.1,31.1
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,33.6,29.3,38.0
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,33.9,29.9,38.5
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,34.6,30.7,39.8
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,38.7,33.7,44.4
GTM,Country,Guatemala,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,44.3,38.5,50.9
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,280.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,360.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,260.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,390.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,330.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,200.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,240.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,240.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,270.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,260.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,250.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,260.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,300.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,280.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,360.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,260.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,390.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,330.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,200.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,240.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,240.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,270.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,260.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,250.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,260.0,,
GTM,Country,Guatemala,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,300.0,,
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,39.5,34.0,45.0
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,49.7,44.0,56.3
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,53.5,47.7,61.4
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,69.8,62.1,79.2
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,56.6,50.0,65.4
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,62.3,54.4,71.8
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,59.0,50.6,67.9
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,48.1,41.5,56.1
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,56.8,48.6,66.3
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,64.3,55.3,75.8
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,50.0,43.1,58.8
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,70.1,59.5,82.5
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,87.1,75.0,95.0
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,39.5,34.6,45.8
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,49.7,43.8,56.0
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,53.5,46.6,60.1
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,69.8,61.4,78.4
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,56.6,48.9,64.0
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,62.3,54.0,71.4
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,59.0,51.3,68.9
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,48.1,41.2,55.7
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,56.8,48.7,66.4
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,64.3,54.5,74.7
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,50.0,42.5,58.1
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,70.1,59.6,82.6
GUY,Country,Guyana,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,87.1,74.2,95.0
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,120.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,140.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,150.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,200.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,160.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,170.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,160.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,130.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,150.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,180.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,140.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,200.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,240.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,120.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,140.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,150.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,200.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,160.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,170.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,160.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,130.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,150.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,180.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,140.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,200.0,,
GUY,Country,Guyana,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,240.0,,
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,33.2,29.9,36.9
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,34.5,30.9,38.8
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,39.0,35.3,43.8
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,37.1,33.9,41.7
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,38.6,35.2,43.8
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,36.1,33.0,41.2
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,38.2,34.6,43.5
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,42.0,38.0,47.0
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,49.9,45.2,56.2
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,40.8,36.8,45.9
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,36.0,32.2,40.3
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,40.5,36.8,45.6
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,41.4,37.5,46.5
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,33.2,29.9,36.8
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,34.5,30.7,38.6
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,39.0,34.6,43.0
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,37.1,33.0,40.7
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,38.6,34.0,42.3
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,36.1,31.6,39.5
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,38.2,33.5,42.1
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,42.0,37.4,46.3
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,49.9,44.3,55.0
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,40.8,36.4,45.3
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,36.0,32.2,40.2
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,40.5,35.9,44.5
HND,Country,Honduras,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,41.4,36.9,45.8
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,250.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,230.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,240.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,210.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,200.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,180.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,170.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,180.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,200.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,160.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,130.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,140.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,140.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,250.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,230.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,240.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,210.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,200.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,180.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,170.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,180.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,200.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,160.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,130.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,140.0,,
HND,Country,Honduras,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,140.0,,
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,47.1,39.3,54.4
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,77.3,65.1,89.1
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,95.0,85.1,95.0
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,95.0,89.4,95.0
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,91.1,75.9,95.0
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,87.4,73.9,95.0
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,80.6,69.0,91.5
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,86.0,74.2,95.0
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,91.2,77.3,95.0
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,87.8,75.2,95.0
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,71.6,60.2,81.9
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,68.2,56.8,78.9
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,62.3,51.6,72.2
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,47.1,40.8,56.4
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,77.3,67.0,91.8
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,95.0,87.4,95.0
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,95.0,93.9,95.0
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,91.1,78.9,95.0
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,87.4,76.5,95.0
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,80.6,71.0,94.0
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,86.0,75.1,95.0
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,91.2,80.3,95.0
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,87.8,76.3,95.0
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,71.6,62.7,85.3
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,68.2,58.9,81.8
HTI,Country,Haiti,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,62.3,53.8,75.3
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,2400.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,3800.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,4900.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,5200.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,4500.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,4400.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,4100.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,4500.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,4900.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,4900.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,4100.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,4000.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,3700.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,2400.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,3800.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,4900.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,5200.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,4500.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,4400.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,4100.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,4500.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,4900.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,4900.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,4100.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,4000.0,,
HTI,Country,Haiti,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,3700.0,,
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,2.7,2.3,3.1
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,1.6,1.3,1.9
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,3.1,2.7,3.6
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,4.5,3.8,5.2
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,6.4,5.4,7.4
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,8.4,7.2,9.6
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,10.6,9.2,12.3
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,13.5,11.4,15.5
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,16.3,13.8,18.7
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,18.0,15.4,20.7
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,17.4,15.0,20.0
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,15.2,13.0,17.6
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,18.0,15.3,20.4
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,2.7,2.2,3.1
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,1.6,1.4,2.0
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,3.1,2.7,3.6
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,4.5,3.9,5.3
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,6.4,5.6,7.6
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,8.4,7.4,9.9
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,10.6,9.2,12.4
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,13.5,11.8,16.0
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,16.3,14.3,19.3
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,18.0,15.7,21.1
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,17.4,15.2,20.2
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,15.2,13.2,17.9
IDN,Country,Indonesia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,18.0,15.8,21.0
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,250.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,170.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,350.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,510.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,750.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,990.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,1200.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,1500.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,1800.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,2000.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,1800.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,1500.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,1700.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,250.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,170.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,350.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,510.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,750.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,990.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,1200.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,1500.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,1800.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,2000.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,1800.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,1500.0,,
IDN,Country,Indonesia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,1700.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,13.7,10.2,18.1
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,17.0,12.2,22.9
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,26.9,18.9,36.2
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,28.3,20.3,39.8
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,35.0,25.7,49.8
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,27.0,19.7,39.8
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,35.7,25.2,50.9
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,38.4,28.3,58.3
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,45.0,32.6,67.6
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,44.4,32.3,66.9
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,44.7,32.5,65.8
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,41.2,30.5,65.4
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,37.4,26.9,58.5
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,13.7,10.3,18.4
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,17.0,12.6,23.7
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,26.9,20.1,38.4
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,28.3,20.2,39.5
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,35.0,24.6,47.6
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,27.0,18.3,37.0
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,35.7,25.0,50.4
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,38.4,25.3,52.2
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,45.0,30.0,62.2
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,44.4,29.5,61.0
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,44.7,30.4,61.5
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,41.2,25.9,55.6
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,37.4,24.0,52.0
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,60.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,70.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,120.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,130.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,170.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,130.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,170.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,190.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,210.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,180.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,180.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,160.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,140.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,60.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,70.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,120.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,130.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,170.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,130.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,170.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,190.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,210.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,180.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,180.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,160.0,,
IRN,Country,Iran (Islamic Republic of),Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,140.0,,
IRQ,Country,Iraq,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
IRQ,Country,Iraq,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
IRQ,Country,Iraq,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
IRQ,Country,Iraq,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,0.0,,
IRQ,Country,Iraq,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,0.0,,
IRQ,Country,Iraq,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,0.0,,
IRQ,Country,Iraq,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,0.0,,
IRQ,Country,Iraq,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,0.0,,
IRQ,Country,Iraq,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,0.0,,
IRQ,Country,Iraq,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,0.0,,
IRQ,Country,Iraq,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,0.0,,
IRQ,Country,Iraq,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,0.0,,
IRQ,Country,Iraq,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,10.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,56.0,51.3,61.2
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,45.8,42.0,50.0
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,45.8,41.9,49.9
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,46.1,42.2,50.2
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,64.7,60.2,70.2
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,74.2,68.6,80.3
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,74.3,69.8,80.1
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,76.5,71.3,81.8
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,76.1,71.7,82.1
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,79.2,74.8,85.6
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,63.8,60.8,68.9
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,76.0,71.8,81.6
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,76.7,73.0,82.3
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,56.0,51.2,61.0
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,45.8,42.0,50.0
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,45.8,42.0,50.1
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,46.1,42.3,50.3
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,64.7,59.6,69.4
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,74.2,68.5,80.2
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,74.3,68.9,79.0
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,76.5,71.5,82.1
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,76.1,70.6,80.7
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,79.2,73.3,83.9
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,63.8,59.1,66.9
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,76.0,70.7,80.3
JAM,Country,Jamaica,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,76.7,71.5,80.6
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,390.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,300.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,300.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,280.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,390.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,410.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,410.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,410.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,400.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,410.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,330.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,380.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,370.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,390.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,300.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,300.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,280.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,390.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,410.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,410.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,410.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,400.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,410.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,330.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,380.0,,
JAM,Country,Jamaica,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,370.0,,
JOR,Country,Jordan,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
JOR,Country,Jordan,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
JOR,Country,Jordan,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
JOR,Country,Jordan,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,0.0,,
JOR,Country,Jordan,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,0.0,,
JOR,Country,Jordan,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,0.0,,
JOR,Country,Jordan,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,10.0,,
JOR,Country,Jordan,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,0.0,,
JOR,Country,Jordan,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,0.0,,
JOR,Country,Jordan,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,0.0,,
JOR,Country,Jordan,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,0.0,,
JOR,Country,Jordan,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,0.0,,
JOR,Country,Jordan,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,0.0,,
KAZ,Country,Kazakhstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,220.0,,
KAZ,Country,Kazakhstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,260.0,,
KAZ,Country,Kazakhstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,300.0,,
KAZ,Country,Kazakhstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,310.0,,
KAZ,Country,Kazakhstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,300.0,,
KAZ,Country,Kazakhstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,350.0,,
KAZ,Country,Kazakhstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,380.0,,
KAZ,Country,Kazakhstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,390.0,,
KAZ,Country,Kazakhstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,360.0,,
KAZ,Country,Kazakhstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,440.0,,
KAZ,Country,Kazakhstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,470.0,,
KAZ,Country,Kazakhstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,480.0,,
KAZ,Country,Kazakhstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,460.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,52.8,44.9,62.1
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,72.3,61.5,85.1
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,58.9,50.1,69.4
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,61.0,51.9,71.9
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,71.5,60.8,84.2
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,90.9,77.3,95.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,92.8,78.9,95.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,85.2,72.4,95.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,81.4,95.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,87.9,95.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,84.1,95.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,84.1,95.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,89.6,76.2,95.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,52.8,44.8,62.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,72.3,61.4,85.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,58.9,50.0,69.3
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,61.0,51.8,71.8
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,71.5,60.7,84.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,90.9,77.2,95.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,92.8,78.8,95.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,85.2,72.3,95.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,81.3,95.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,87.8,95.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,84.0,95.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,83.9,95.0
KEN,Country,Kenya,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,89.6,76.0,95.0
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,41600.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,55600.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,44400.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,44600.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,50300.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,59000.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,59300.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,53100.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,57500.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,59300.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,54000.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,52400.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,46400.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,41600.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,55600.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,44400.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,44600.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,50300.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,59000.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,59300.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,53100.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,57500.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,59300.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,54000.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,52400.0,,
KEN,Country,Kenya,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,46400.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,48.1,43.2,53.5
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,35.5,31.8,39.8
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,63.2,56.7,69.3
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,68.3,61.2,74.9
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,73.5,66.9,81.1
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,53.4,49.1,58.6
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,67.5,62.2,72.3
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,70.2,64.8,75.1
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,73.5,68.6,80.0
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,71.0,65.2,76.5
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,93.9,87.6,95.0
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,91.5,84.3,95.0
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,93.0,95.0
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,48.1,43.3,53.6
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,35.5,31.7,39.6
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,63.2,57.7,70.5
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,68.3,62.3,76.2
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,73.5,66.7,80.9
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,53.4,48.6,58.0
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,67.5,62.9,73.2
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,70.2,65.6,75.9
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,73.5,67.5,78.7
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,71.0,66.0,77.4
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,93.9,87.0,95.0
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,91.5,84.8,95.0
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,95.0,95.0
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,50.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,40.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,90.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,100.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,110.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,90.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,110.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,120.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,130.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,130.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,170.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,160.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,180.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,50.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,40.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,90.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,100.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,110.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,90.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,110.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,120.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,130.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,130.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,170.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,160.0,,
KGZ,Country,Kyrgyzstan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,180.0,,
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,37.2,31.7,42.1
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,49.0,42.1,56.3
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,53.5,46.0,61.6
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,60.8,52.6,69.2
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,68.7,60.3,77.9
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,79.8,69.4,90.6
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,81.7,71.2,93.4
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,92.8,81.0,95.0
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,87.2,76.6,95.0
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,82.5,72.5,94.0
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,89.4,78.1,95.0
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,75.4,65.5,86.4
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,88.6,76.8,95.0
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,37.2,32.9,43.7
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,49.0,42.7,57.1
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,53.5,46.5,62.3
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,60.8,53.5,70.3
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,68.7,60.6,78.3
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,79.8,70.3,91.9
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,81.7,71.5,93.8
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,92.8,82.0,95.0
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,87.2,77.0,95.0
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,82.5,72.4,93.9
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,89.4,78.6,95.0
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,75.4,65.8,86.8
KHM,Country,Cambodia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,88.6,77.4,95.0
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,550.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,660.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,670.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,700.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,720.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,770.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,720.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,760.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,660.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,590.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,600.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,470.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,530.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,550.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,660.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,670.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,700.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,720.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,770.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,720.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,760.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,660.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,590.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,600.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,470.0,,
KHM,Country,Cambodia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,530.0,,
KNA,Country,Saint Kitts and Nevis,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
KNA,Country,Saint Kitts and Nevis,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
KNA,Country,Saint Kitts and Nevis,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
KNA,Country,Saint Kitts and Nevis,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,0.0,,
KNA,Country,Saint Kitts and Nevis,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,0.0,,
KNA,Country,Saint Kitts and Nevis,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,0.0,,
KNA,Country,Saint Kitts and Nevis,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,0.0,,
KNA,Country,Saint Kitts and Nevis,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,0.0,,
KNA,Country,Saint Kitts and Nevis,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,0.0,,
KNA,Country,Saint Kitts and Nevis,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,0.0,,
KNA,Country,Saint Kitts and Nevis,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,0.0,,
KNA,Country,Saint Kitts and Nevis,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,0.0,,
KNA,Country,Saint Kitts and Nevis,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,0.0,,
KWT,Country,Kuwait,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,10.0,,
KWT,Country,Kuwait,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
KWT,Country,Kuwait,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,10.0,,
KWT,Country,Kuwait,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,0.0,,
KWT,Country,Kuwait,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,10.0,,
KWT,Country,Kuwait,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,0.0,,
KWT,Country,Kuwait,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,0.0,,
KWT,Country,Kuwait,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,0.0,,
KWT,Country,Kuwait,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,10.0,,
KWT,Country,Kuwait,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,10.0,,
KWT,Country,Kuwait,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,10.0,,
KWT,Country,Kuwait,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,10.0,,
KWT,Country,Kuwait,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,10.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,12.4,10.5,14.7
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,22.9,19.0,26.6
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,22.6,19.1,25.8
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,25.0,21.1,29.1
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,14.0,12.0,16.4
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,15.6,13.3,17.9
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,35.0,30.0,40.5
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,35.1,30.4,40.4
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,41.3,35.3,46.4
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,30.6,26.8,35.3
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,36.4,31.7,41.4
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,60.7,52.1,68.9
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,54.3,46.6,61.4
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,12.4,10.5,14.7
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,22.9,19.7,27.5
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,22.6,19.8,26.6
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,25.0,21.5,29.6
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,14.0,12.0,16.4
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,15.6,13.7,18.4
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,35.0,30.2,40.7
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,35.1,30.5,40.5
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,41.3,36.7,48.2
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,30.6,26.5,34.9
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,36.4,32.1,41.9
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,60.7,53.4,70.6
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,54.3,48.0,63.2
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,30.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,50.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,50.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,60.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,30.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,40.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,80.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,80.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,90.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,70.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,80.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,130.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,110.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,30.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,50.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,50.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,60.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,30.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,40.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,80.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,80.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,90.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,70.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,80.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,130.0,,
LAO,Country,Lao People's Democratic Republic,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,110.0,,
LBN,Country,Lebanon,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
LBN,Country,Lebanon,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
LBN,Country,Lebanon,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
LBN,Country,Lebanon,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,10.0,,
LBN,Country,Lebanon,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,0.0,,
LBN,Country,Lebanon,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,0.0,,
LBN,Country,Lebanon,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,0.0,,
LBN,Country,Lebanon,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,0.0,,
LBN,Country,Lebanon,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,0.0,,
LBN,Country,Lebanon,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,0.0,,
LBN,Country,Lebanon,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,10.0,,
LBN,Country,Lebanon,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,10.0,,
LBN,Country,Lebanon,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,10.0,,
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,21.2,17.2,25.3
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,31.6,25.9,38.6
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,32.9,27.2,38.5
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,26.4,21.4,32.0
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,28.2,22.8,34.5
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,54.4,44.7,66.9
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,66.5,54.2,83.3
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,76.9,62.4,95.0
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,91.4,73.4,95.0
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,93.5,74.2,95.0
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,69.6,55.2,87.3
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,77.7,95.0
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,86.3,67.9,95.0
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,21.2,17.8,26.2
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,31.6,25.8,38.5
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,32.9,28.1,39.7
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,26.4,21.8,32.6
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,28.2,23.0,34.8
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,54.4,44.3,66.2
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,66.5,53.2,81.7
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,76.9,59.4,94.8
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,91.4,72.8,95.0
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,93.5,74.0,95.0
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,69.6,55.5,87.8
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,75.8,95.0
LBR,Country,Liberia,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,86.3,66.4,95.0
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,560.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,810.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,850.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,640.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,650.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,1200.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,1400.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,1600.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,1800.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,1800.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,1400.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,1900.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,1700.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,560.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,810.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,850.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,640.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,650.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,1200.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,1400.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,1600.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,1800.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,1800.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,1400.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,1900.0,,
LBR,Country,Liberia,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,1700.0,,
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,1.0,1.0,1.0
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,1.0,1.0,1.0
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,1.0,1.0,1.0
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,1.0,1.0,1.0
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,1.0,1.0,1.0
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,1.0,1.0,1.0
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,57.6,53.2,63.2
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,56.4,51.6,61.2
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,68.1,63.0,74.6
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,67.4,61.0,73.8
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,65.6,58.8,71.8
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,66.0,58.9,73.0
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,67.4,59.3,74.7
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,1.0,1.0,1.0
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,1.0,1.0,1.0
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,1.0,1.0,1.0
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,1.0,1.0,1.0
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,1.0,1.0,1.0
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,1.0,1.0,1.0
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,57.6,52.5,62.4
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,56.4,52.0,61.6
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,68.1,62.1,73.6
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,67.4,61.5,74.4
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,65.6,60.0,73.3
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,66.0,59.6,73.8
LBY,Country,Libya,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,67.4,60.8,76.5
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,0.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,0.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,0.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,50.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,50.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,60.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,60.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,60.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,60.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,60.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,0.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,0.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,0.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,0.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,0.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,0.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,50.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,50.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,60.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,60.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,60.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,60.0,,
LBY,Country,Libya,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,60.0,,
LKA,Country,Sri Lanka,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,10.0,,
LKA,Country,Sri Lanka,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,10.0,,
LKA,Country,Sri Lanka,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,10.0,,
LKA,Country,Sri Lanka,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,10.0,,
LKA,Country,Sri Lanka,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,10.0,,
LKA,Country,Sri Lanka,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,10.0,,
LKA,Country,Sri Lanka,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,20.0,,
LKA,Country,Sri Lanka,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,20.0,,
LKA,Country,Sri Lanka,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,20.0,,
LKA,Country,Sri Lanka,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,20.0,,
LKA,Country,Sri Lanka,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,20.0,,
LKA,Country,Sri Lanka,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,20.0,,
LKA,Country,Sri Lanka,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,20.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,66.4,55.7,74.3
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,91.4,77.6,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,92.6,78.1,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,89.9,75.5,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,95.0,81.5,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,84.3,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,93.9,80.6,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,77.1,65.1,84.6
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,87.5,72.3,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,85.9,70.8,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,90.0,72.9,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,86.8,69.5,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,89.4,71.7,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,66.4,59.4,79.2
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,91.4,81.6,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,92.6,84.1,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,89.9,80.2,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,95.0,87.1,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,89.1,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,93.9,85.3,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,77.1,70.3,91.3
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,87.5,79.3,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,85.9,77.2,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,90.0,80.6,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,86.8,77.9,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,89.4,78.9,95.0
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,8000.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,10900.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,10700.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,10100.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,10600.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,10500.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,9600.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,7500.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,8100.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,7600.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,7500.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,6800.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,6500.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,8000.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,10900.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,10700.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,10100.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,10600.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,10500.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,9600.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,7500.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,8100.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,7600.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,7500.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,6800.0,,
LSO,Country,Lesotho,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,6500.0,,
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,21.5,18.9,24.3
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,21.3,18.8,24.1
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,33.7,30.1,37.8
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,31.7,28.2,35.3
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,37.0,33.4,41.6
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,31.4,28.4,34.6
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,41.1,37.6,45.7
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,40.9,37.5,44.9
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,44.5,40.8,49.3
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,55.1,50.2,61.2
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,52.1,47.2,57.3
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,52.4,47.5,57.7
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,62.8,57.3,69.4
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,21.5,18.9,24.3
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,21.3,18.8,24.1
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,33.7,30.0,37.7
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,31.7,28.4,35.5
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,37.0,32.9,41.0
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,31.4,28.5,34.7
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,41.1,37.0,45.0
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,40.9,37.3,44.7
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,44.5,40.2,48.6
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,55.1,49.6,60.5
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,52.1,47.3,57.4
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,52.4,47.6,57.8
MAR,Country,Morocco,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,62.8,56.9,69.0
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,120.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,120.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,200.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,180.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,210.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,170.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,220.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,210.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,220.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,250.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,230.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,220.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,250.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,120.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,120.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,200.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,180.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,210.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,170.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,220.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,210.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,220.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,250.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,230.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,220.0,,
MAR,Country,Morocco,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,250.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,67.6,57.1,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,65.1,55.1,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,67.5,57.0,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,64.0,54.2,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,72.0,60.7,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,77.1,65.2,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,79.4,67.0,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,88.6,75.0,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,79.6,67.2,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,88.8,74.8,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,77.6,65.6,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,86.6,73.3,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,81.3,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,67.6,44.5,80.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,65.1,42.7,76.9
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,67.5,44.3,79.8
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,64.0,42.0,75.6
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,72.0,47.5,85.6
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,77.1,50.7,91.2
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,79.4,52.2,94.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,88.6,58.2,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,79.6,52.4,94.3
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,88.8,58.6,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,77.6,51.0,91.8
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,86.6,56.8,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,63.5,95.0
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,120.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,120.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,140.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,150.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,150.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,180.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,200.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,210.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,180.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,200.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,160.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,170.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,190.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,120.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,120.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,140.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,150.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,150.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,180.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,200.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,210.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,180.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,200.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,160.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,170.0,,
MDA,Country,Republic of Moldova,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,190.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,1.7,1.4,2.1
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,9.2,7.6,11.1
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,5.9,4.8,7.0
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,4.2,3.6,5.0
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,3.5,3.0,4.2
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,2.9,2.5,3.4
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,1.5,1.2,1.7
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,4.7,4.0,5.6
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,11.4,9.4,13.5
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,12.8,10.8,14.9
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,9.1,7.7,10.8
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,12.5,10.4,15.3
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,12.4,10.2,15.2
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,1.7,1.4,2.1
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,9.2,7.6,11.1
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,5.9,5.0,7.3
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,4.2,3.6,5.0
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,3.5,3.0,4.1
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,2.9,2.5,3.5
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,1.5,1.3,1.7
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,4.7,4.0,5.7
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,11.4,9.6,13.7
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,12.8,10.9,15.1
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,9.1,7.7,10.8
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,12.5,10.2,15.1
MDG,Country,Madagascar,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,12.4,10.2,15.2
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,20.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,110.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,80.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,60.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,60.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,50.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,30.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,110.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,280.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,340.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,260.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,380.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,400.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,20.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,110.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,80.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,60.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,60.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,50.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,30.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,110.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,280.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,340.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,260.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,380.0,,
MDG,Country,Madagascar,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,400.0,,
MDV,Country,Maldives,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
MDV,Country,Maldives,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
MDV,Country,Maldives,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
MDV,Country,Maldives,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,0.0,,
MDV,Country,Maldives,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,0.0,,
MDV,Country,Maldives,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,0.0,,
MDV,Country,Maldives,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,0.0,,
MDV,Country,Maldives,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,0.0,,
MDV,Country,Maldives,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,0.0,,
MDV,Country,Maldives,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,0.0,,
MDV,Country,Maldives,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,0.0,,
MDV,Country,Maldives,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,0.0,,
MDV,Country,Maldives,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,0.0,,
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,36.1,29.8,43.4
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,50.1,40.3,60.7
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,54.2,44.5,65.6
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,32.4,26.5,39.7
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,35.6,28.4,43.5
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,41.0,32.7,51.0
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,37.2,29.3,45.3
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,36.8,28.8,45.8
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,38.4,29.4,48.7
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,31.1,23.8,40.0
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,32.1,24.2,41.2
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,38.6,29.3,50.5
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,33.1,24.5,43.7
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,36.1,30.1,43.9
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,50.1,41.4,62.3
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,54.2,44.7,66.0
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,32.4,26.4,39.5
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,35.6,29.1,44.5
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,41.0,32.9,51.3
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,37.2,30.6,47.3
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,36.8,29.6,46.9
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,38.4,30.3,50.2
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,31.1,24.2,40.6
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,32.1,25.0,42.5
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,38.6,29.4,50.9
MLI,Country,Mali,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,33.1,25.0,44.6
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,2500.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,3500.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,3800.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,2200.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,2400.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,2700.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,2400.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,2300.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,2400.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,1900.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,1900.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,2200.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,1900.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,2500.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,3500.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,3800.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,2200.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,2400.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,2700.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,2400.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,2300.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,2400.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,1900.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,1900.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,2200.0,,
MLI,Country,Mali,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,1900.0,,
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,41.4,35.1,48.9
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,49.6,41.0,57.0
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,57.3,48.5,65.5
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,60.6,51.3,68.7
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,70.6,60.3,80.8
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,74.0,62.9,84.7
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,81.0,69.4,93.1
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,81.7,69.7,92.6
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,86.1,73.2,95.0
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,86.0,73.0,95.0
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,81.4,68.3,94.9
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,21.9,18.2,25.9
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,43.3,35.7,51.4
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,41.4,35.0,48.8
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,49.6,43.3,60.1
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,57.3,50.1,67.6
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,60.6,53.4,71.6
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,70.6,61.7,82.7
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,74.0,64.6,87.0
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,81.0,70.5,94.5
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,81.7,72.1,95.0
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,86.1,75.6,95.0
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,86.0,74.5,95.0
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,81.4,69.8,95.0
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,21.9,18.6,26.4
MMR,Country,Myanmar,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,43.3,36.5,52.6
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,1900.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,2300.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,2700.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,2900.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,3400.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,3700.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,4100.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,4100.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,4300.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,4200.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,3900.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,1000.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,1900.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,1900.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,2300.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,2700.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,2900.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,3400.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,3700.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,4100.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,4100.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,4300.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,4200.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,3900.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,1000.0,,
MMR,Country,Myanmar,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,1900.0,,
MNG,Country,Mongolia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
MNG,Country,Mongolia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
MNG,Country,Mongolia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
MNG,Country,Mongolia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,0.0,,
MNG,Country,Mongolia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,0.0,,
MNG,Country,Mongolia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,0.0,,
MNG,Country,Mongolia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,0.0,,
MNG,Country,Mongolia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,10.0,,
MNG,Country,Mongolia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,0.0,,
MNG,Country,Mongolia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,0.0,,
MNG,Country,Mongolia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,0.0,,
MNG,Country,Mongolia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,0.0,,
MNG,Country,Mongolia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,0.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,20.8,17.7,23.4
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,44.3,38.2,49.9
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,68.7,59.1,76.9
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,73.3,62.1,82.3
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,82.6,70.0,93.1
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,84.1,72.9,93.3
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,78.1,67.6,86.3
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,86.4,74.2,95.0
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,86.9,74.3,95.0
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,88.7,77.9,95.0
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,84.3,72.2,93.8
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,88.8,76.3,95.0
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,92.5,78.7,95.0
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,20.8,18.5,24.5
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,44.3,39.4,51.5
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,68.7,61.4,80.0
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,73.3,65.2,86.5
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,82.6,73.2,95.0
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,84.1,75.9,95.0
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,78.1,70.7,90.3
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,86.4,77.6,95.0
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,86.9,78.2,95.0
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,88.7,79.3,95.0
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,84.3,75.7,95.0
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,88.8,80.1,95.0
MOZ,Country,Mozambique,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,92.5,83.0,95.0
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,22300.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,48800.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,77100.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,83800.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,94900.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,99800.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,95300.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,108000.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,109000.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,112000.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,107000.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,113000.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,116000.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,22300.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,48800.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,77100.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,83800.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,94900.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,99800.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,95300.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,108000.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,109000.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,112000.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,107000.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,113000.0,,
MOZ,Country,Mozambique,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,116000.0,,
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,8.3,7.1,9.8
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,8.8,7.3,10.3
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,4.2,3.6,5.0
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,9.0,7.6,10.9
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,57.8,49.0,69.9
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,53.8,44.5,65.4
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,17.3,14.2,21.7
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,12.1,9.9,15.2
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,19.4,15.4,25.2
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,34.5,26.8,46.0
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,20.0,15.6,27.5
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,7.3,5.5,10.6
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,22.5,16.4,33.5
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,8.3,7.1,9.7
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,8.8,7.5,10.5
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,4.2,3.6,5.1
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,9.0,7.5,10.8
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,57.8,47.8,68.2
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,53.8,44.4,65.2
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,17.3,13.7,21.0
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,12.1,9.7,14.9
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,19.4,14.9,24.4
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,34.5,25.9,44.4
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,20.0,14.5,25.6
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,7.3,5.0,9.7
MRT,Country,Mauritania,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,22.5,15.2,30.9
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,30.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,30.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,20.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,30.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,180.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,160.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,50.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,30.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,50.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,90.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,50.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,20.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,60.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,30.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,30.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,20.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,30.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,180.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,160.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,50.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,30.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,50.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,90.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,50.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,20.0,,
MRT,Country,Mauritania,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,60.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,26.3,21.5,29.0
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,48.1,39.8,53.4
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,58.2,47.9,64.2
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,66.0,53.6,74.2
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,70.0,56.9,78.4
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,79.6,64.7,87.7
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,85.4,69.3,93.8
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,92.2,74.8,95.0
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,80.0,95.0
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,94.9,76.5,95.0
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,79.9,95.0
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,76.7,95.0
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,90.5,72.3,95.0
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,26.3,23.8,32.1
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,48.1,43.3,58.1
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,58.2,52.8,70.8
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,66.0,58.8,81.3
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,70.0,62.5,86.0
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,79.6,72.3,95.0
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,85.4,77.8,95.0
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,92.2,83.6,95.0
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,90.2,95.0
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,94.9,86.0,95.0
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,90.3,95.0
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,86.5,95.0
MWI,Country,Malawi,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,90.5,82.2,95.0
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,14000.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,25300.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,30200.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,34000.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,35200.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,38800.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,40400.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,42400.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,44500.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,40600.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,40300.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,36800.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,33000.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,14000.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,25300.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,30200.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,34000.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,35200.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,38800.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,40400.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,42400.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,44500.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,40600.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,40300.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,36800.0,,
MWI,Country,Malawi,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,33000.0,,
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,63.7,52.9,76.8
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,66.7,55.1,80.2
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,65.8,56.2,78.5
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,63.0,51.0,75.0
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,70.1,57.7,84.1
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,79.4,65.1,94.2
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,95.0,80.5,95.0
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,95.0,78.8,95.0
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,78.0,95.0
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,73.5,95.0
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,69.6,95.0
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,74.5,95.0
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,77.9,95.0
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,63.7,52.9,76.7
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,66.7,55.4,80.7
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,65.8,55.2,77.2
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,63.0,52.9,77.8
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,70.1,58.4,85.1
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,79.4,66.9,95.0
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,95.0,83.8,95.0
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,95.0,80.7,95.0
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,80.1,95.0
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,77.4,95.0
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,76.4,95.0
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,81.1,95.0
MYS,Country,Malaysia,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,80.9,95.0
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,270.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,290.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,290.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,270.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,300.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,320.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,310.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,260.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,260.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,220.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,250.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,210.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,180.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,270.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,290.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,290.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,270.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,300.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,320.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,310.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,260.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,260.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,220.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,250.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,210.0,,
MYS,Country,Malaysia,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,180.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,65.7,56.0,73.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,71.2,60.6,79.8
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,63.1,54.0,69.6
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,79.8,68.2,89.2
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,92.5,79.1,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,86.1,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,95.0,90.7,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,95.0,95.0,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,95.0,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,95.0,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,95.0,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,95.0,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,95.0,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,65.7,59.1,77.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,71.2,63.5,83.6
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,63.1,57.1,73.6
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,79.8,71.5,93.4
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,92.5,83.9,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,89.4,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,95.0,94.1,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,95.0,95.0,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,95.0,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,95.0,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,95.0,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,95.0,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,95.0,95.0
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,7700.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,8400.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,7500.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,9400.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,10800.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,11500.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,11800.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,12600.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,12500.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,12500.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,15000.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,13400.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,11700.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,7700.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,8400.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,7500.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,9400.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,10800.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,11500.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,11800.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,12600.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,12500.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,12500.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,15000.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,13400.0,,
NAM,Country,Namibia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,11700.0,,
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,79.1,68.8,91.5
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,60.4,53.8,70.0
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,52.6,46.5,60.1
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,52.1,46.9,59.1
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,62.5,57.0,70.9
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,41.3,37.2,46.6
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,66.2,59.3,75.8
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,42.0,37.9,47.3
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,39.9,36.0,44.7
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,33.5,30.3,37.5
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,27.4,24.8,31.1
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,26.4,23.8,29.8
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,32.0,28.7,36.2
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,79.1,68.3,90.8
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,60.4,52.1,67.9
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,52.6,46.0,59.5
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,52.1,45.9,57.9
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,62.5,55.0,68.4
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,41.3,36.5,45.8
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,66.2,57.9,73.9
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,42.0,37.3,46.5
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,39.9,35.5,44.2
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,33.5,29.9,37.1
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,27.4,24.2,30.3
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,26.4,23.5,29.4
NER,Country,Niger,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,32.0,28.2,35.7
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,2100.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,1600.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,1300.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,1300.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,1500.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,980.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,1500.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,980.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,940.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,790.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,650.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,630.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,760.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,2100.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,1600.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,1300.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,1300.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,1500.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,980.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,1500.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,980.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,940.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,790.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,650.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,630.0,,
NER,Country,Niger,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,760.0,,
NGA,Country,Nigeria,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,26800.0,,
NGA,Country,Nigeria,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,32300.0,,
NGA,Country,Nigeria,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,37900.0,,
NGA,Country,Nigeria,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,51400.0,,
NGA,Country,Nigeria,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,60100.0,,
NGA,Country,Nigeria,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,52300.0,,
NGA,Country,Nigeria,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,55200.0,,
NGA,Country,Nigeria,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,49400.0,,
NGA,Country,Nigeria,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,42300.0,,
NGA,Country,Nigeria,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,41700.0,,
NGA,Country,Nigeria,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,36700.0,,
NGA,Country,Nigeria,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,34600.0,,
NGA,Country,Nigeria,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,32300.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,67.6,53.7,87.5
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,89.2,69.3,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,95.0,81.0,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,79.0,61.9,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,78.5,62.1,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,90.9,72.5,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,83.1,64.4,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,79.9,62.0,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,75.1,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,82.0,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,83.1,65.2,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,91.3,69.5,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,75.6,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,67.6,52.3,85.2
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,89.2,68.9,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,95.0,81.9,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,79.0,62.8,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,78.5,61.7,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,90.9,71.0,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,83.1,66.7,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,79.9,63.4,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,76.4,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,84.6,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,83.1,65.1,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,91.3,70.6,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,79.1,95.0
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,90.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,120.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,150.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,110.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,110.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,130.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,120.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,110.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,130.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,140.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,110.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,120.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,120.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,90.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,120.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,150.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,110.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,110.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,130.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,120.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,110.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,130.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,140.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,110.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,120.0,,
NIC,Country,Nicaragua,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,120.0,,
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,15.1,12.7,18.0
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,23.0,18.7,26.8
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,29.4,25.0,33.9
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,35.2,29.6,41.8
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,43.1,36.4,50.9
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,41.2,34.6,47.6
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,55.0,46.5,64.9
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,62.2,53.1,73.2
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,50.9,43.6,58.1
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,45.7,39.8,53.7
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,48.2,41.3,55.7
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,73.5,63.3,85.0
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,80.2,69.2,91.5
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,15.1,12.7,17.9
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,23.0,19.8,28.4
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,29.4,25.6,34.7
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,35.2,29.7,42.0
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,43.1,36.5,50.9
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,41.2,35.6,49.0
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,55.0,46.6,65.1
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,62.2,52.9,72.9
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,50.9,44.5,59.3
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,45.7,38.9,52.6
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,48.2,41.7,56.3
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,73.5,63.6,85.4
NPL,Country,Nepal,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,80.2,70.3,92.9
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,70.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,100.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,130.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,140.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,160.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,150.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,180.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,190.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,150.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,120.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,120.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,180.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,180.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,70.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,100.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,130.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,140.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,160.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,150.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,180.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,190.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,150.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,120.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,120.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,180.0,,
NPL,Country,Nepal,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,180.0,,
OMN,Country,Oman,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,30.0,,
OMN,Country,Oman,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,30.0,,
OMN,Country,Oman,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,30.0,,
OMN,Country,Oman,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,30.0,,
OMN,Country,Oman,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,30.0,,
OMN,Country,Oman,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,30.0,,
OMN,Country,Oman,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,40.0,,
OMN,Country,Oman,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,30.0,,
OMN,Country,Oman,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,30.0,,
OMN,Country,Oman,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,40.0,,
OMN,Country,Oman,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,30.0,,
OMN,Country,Oman,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,50.0,,
OMN,Country,Oman,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,40.0,,
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,3.1,2.6,3.8
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,7.4,6.0,8.9
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,3.9,3.4,4.6
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,9.7,8.0,11.4
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,4.0,3.3,4.6
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,12.2,10.3,14.3
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,6.7,5.7,7.7
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,8.9,7.5,10.2
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,14.4,12.3,16.3
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,17.3,14.9,19.8
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,4.9,4.2,5.6
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,18.3,15.6,20.9
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,12.2,10.6,13.9
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,3.1,2.6,3.8
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,7.4,6.2,9.2
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,3.9,3.3,4.5
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,9.7,8.3,11.8
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,4.0,3.4,4.7
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,12.2,10.5,14.5
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,6.7,5.7,7.8
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,8.9,7.7,10.4
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,14.4,12.7,16.8
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,17.3,15.2,20.1
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,4.9,4.3,5.7
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,18.3,16.0,21.4
PAK,Country,Pakistan,South Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,12.2,10.7,14.1
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,20.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,70.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,40.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,130.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,60.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,210.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,130.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,180.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,320.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,420.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,130.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,500.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,350.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,20.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,70.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,40.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,130.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,60.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,210.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,130.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,180.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,320.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,420.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,130.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,500.0,,
PAK,Country,Pakistan,South Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,350.0,,
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,68.4,62.7,76.7
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,77.6,70.2,86.3
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,76.4,69.0,84.7
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,88.4,76.6,95.0
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,75.1,68.7,83.8
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,82.0,73.5,91.5
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,75.4,68.4,84.1
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,80.1,73.1,87.4
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,73.8,67.4,81.7
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,64.6,58.1,71.5
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,62.9,56.9,70.0
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,83.8,74.9,92.4
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,73.9,65.9,82.3
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,68.4,61.1,74.8
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,77.6,69.8,85.7
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,76.4,68.8,84.6
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,88.4,78.0,95.0
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,75.1,67.3,82.2
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,82.0,73.5,91.4
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,75.4,67.7,83.2
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,80.1,73.4,87.8
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,73.8,66.7,80.9
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,64.6,58.5,71.9
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,62.9,56.6,69.6
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,83.8,76.1,93.8
PAN,Country,Panama,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,73.9,66.4,82.9
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,150.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,180.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,180.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,190.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,180.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,190.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,180.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,200.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,190.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,160.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,150.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,200.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,170.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,150.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,180.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,180.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,190.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,180.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,190.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,180.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,200.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,190.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,160.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,150.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,200.0,,
PAN,Country,Panama,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,170.0,,
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,36.5,31.8,42.3
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,55.4,47.9,64.2
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,66.2,58.2,76.9
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,68.3,60.1,79.1
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,69.2,61.5,81.3
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,64.4,56.3,75.4
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,67.2,58.4,77.7
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,68.6,59.7,80.1
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,78.5,68.1,93.2
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,85.8,73.6,95.0
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,85.5,74.0,95.0
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,80.4,69.1,95.0
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,84.3,72.4,95.0
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,36.5,31.5,41.8
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,55.4,47.9,64.2
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,66.2,57.0,75.2
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,68.3,59.0,77.7
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,69.2,58.9,77.8
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,64.4,55.1,73.7
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,67.2,58.2,77.5
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,68.6,58.8,78.8
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,78.5,66.1,90.3
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,85.8,72.6,95.0
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,85.5,71.0,95.0
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,80.4,67.8,93.6
PER,Country,Peru,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,84.3,70.0,95.0
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,400.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,600.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,700.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,710.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,720.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,680.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,740.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,770.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,910.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,1000.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,1100.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,1000.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,1100.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,400.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,600.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,700.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,710.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,720.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,680.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,740.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,770.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,910.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,1000.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,1100.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,1000.0,,
PER,Country,Peru,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,1100.0,,
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,13.6,11.2,17.0
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,16.4,13.2,19.6
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,13.9,11.5,16.6
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,8.5,7.0,10.4
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,11.9,9.5,14.3
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,13.9,11.4,16.7
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,15.8,12.8,19.4
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,16.4,13.2,20.1
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,17.5,14.0,21.1
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,21.8,17.5,26.7
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,21.5,17.3,26.2
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,13.3,10.8,16.2
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,6.4,5.2,7.6
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,13.6,10.9,16.7
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,16.4,13.6,20.2
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,13.9,11.6,16.7
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,8.5,7.0,10.4
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,11.9,9.8,14.7
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,13.9,11.6,17.0
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,15.8,12.8,19.5
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,16.4,13.4,20.4
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,17.5,14.6,22.0
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,21.8,17.8,27.1
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,21.5,17.6,26.7
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,13.3,10.9,16.3
PHL,Country,Philippines,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,6.4,5.3,7.8
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,10.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,20.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,20.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,10.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,20.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,30.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,40.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,50.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,70.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,100.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,110.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,80.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,50.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,10.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,20.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,20.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,10.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,20.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,30.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,40.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,50.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,70.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,100.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,110.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,80.0,,
PHL,Country,Philippines,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,50.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,4.5,3.5,5.2
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,13.6,10.6,16.2
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,20.9,16.1,24.1
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,27.8,21.2,32.2
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,34.5,26.8,40.0
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,29.0,22.8,33.4
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,33.1,26.3,37.6
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,40.3,31.2,46.7
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,50.3,39.7,58.3
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,64.2,52.7,75.3
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,47.1,38.0,54.8
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,51.6,41.8,60.3
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,50.7,40.7,59.1
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,4.5,3.8,5.8
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,13.6,11.4,17.4
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,20.9,18.0,27.0
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,27.8,24.0,36.5
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,34.5,29.7,44.3
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,29.0,25.1,36.9
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,33.1,29.1,41.7
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,40.3,34.8,51.9
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,50.3,43.3,63.8
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,64.2,54.8,78.2
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,47.1,40.4,58.2
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,51.6,44.2,63.7
PNG,Country,Papua New Guinea,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,50.7,43.6,63.2
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,70.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,210.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,330.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,450.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,570.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,500.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,580.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,730.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,960.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,1300.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,1000.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,1200.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,1200.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,70.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,210.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,330.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,450.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,570.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,500.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,580.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,730.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,960.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,1300.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,1000.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,1200.0,,
PNG,Country,Papua New Guinea,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,1200.0,,
PRY,Country,Paraguay,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,56.7,51.7,61.6
PRY,Country,Paraguay,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,64.3,59.0,69.9
PRY,Country,Paraguay,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,64.5,59.6,70.3
PRY,Country,Paraguay,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,63.2,58.7,68.9
PRY,Country,Paraguay,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,74.9,68.7,80.9
PRY,Country,Paraguay,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,61.4,56.6,66.4
PRY,Country,Paraguay,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,63.7,58.7,69.2
PRY,Country,Paraguay,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,59.3,54.4,64.1
PRY,Country,Paraguay,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,56.7,52.3,62.2
PRY,Country,Paraguay,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,64.3,59.1,70.0
PRY,Country,Paraguay,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,64.5,59.1,69.7
PRY,Country,Paraguay,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,63.2,57.9,67.9
PRY,Country,Paraguay,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,74.9,69.4,81.7
PRY,Country,Paraguay,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,61.4,56.8,66.7
PRY,Country,Paraguay,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,63.7,58.6,69.1
PRY,Country,Paraguay,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,59.3,54.8,64.5
PRY,Country,Paraguay,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,170.0,,
PRY,Country,Paraguay,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,210.0,,
PRY,Country,Paraguay,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,210.0,,
PRY,Country,Paraguay,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,220.0,,
PRY,Country,Paraguay,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,250.0,,
PRY,Country,Paraguay,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,200.0,,
PRY,Country,Paraguay,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,220.0,,
PRY,Country,Paraguay,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,210.0,,
PRY,Country,Paraguay,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,170.0,,
PRY,Country,Paraguay,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,210.0,,
PRY,Country,Paraguay,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,210.0,,
PRY,Country,Paraguay,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,220.0,,
PRY,Country,Paraguay,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,250.0,,
PRY,Country,Paraguay,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,200.0,,
PRY,Country,Paraguay,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,220.0,,
PRY,Country,Paraguay,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,210.0,,
QAT,Country,Qatar,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
QAT,Country,Qatar,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
QAT,Country,Qatar,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
QAT,Country,Qatar,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,0.0,,
QAT,Country,Qatar,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,0.0,,
QAT,Country,Qatar,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,0.0,,
QAT,Country,Qatar,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,0.0,,
QAT,Country,Qatar,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,0.0,,
QAT,Country,Qatar,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,0.0,,
QAT,Country,Qatar,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,0.0,,
QAT,Country,Qatar,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,0.0,,
QAT,Country,Qatar,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,0.0,,
QAT,Country,Qatar,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,0.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,69.6,57.4,78.3
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,95.0,92.1,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,95.0,81.1,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,95.0,82.8,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,95.0,85.7,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,94.0,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,95.0,81.3,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,91.1,75.4,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,91.5,76.9,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,85.1,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,86.2,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,83.0,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,81.0,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,69.6,61.8,84.3
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,95.0,95.0,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,95.0,85.2,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,95.0,88.6,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,95.0,91.9,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,95.0,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,95.0,86.3,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,91.1,80.8,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,91.5,81.3,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,89.4,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,90.0,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,87.9,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,85.5,95.0
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,6900.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,10500.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,9000.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,9200.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,9400.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,10000.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,8500.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,7800.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,7600.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,8100.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,7800.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,7200.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,6600.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,6900.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,10500.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,9000.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,9200.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,9400.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,10000.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,8500.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,7800.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,7600.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,8100.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,7800.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,7200.0,,
RWA,Country,Rwanda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,6600.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,1.0,1.0,1.0
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,29.3,25.7,32.5
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,36.8,32.6,41.0
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,53.2,47.0,58.8
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,51.5,45.4,57.5
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,79.0,71.4,88.0
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,95.0,87.9,95.0
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,89.1,81.0,95.0
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,79.6,72.3,88.5
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,70.4,63.9,79.5
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,73.7,65.9,81.4
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,73.7,67.2,82.7
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,48.4,42.9,53.1
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,1.0,1.0,1.0
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,29.3,26.4,33.3
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,36.8,33.0,41.6
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,53.2,48.2,60.3
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,51.5,46.1,58.3
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,79.0,71.0,87.5
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,95.0,88.9,95.0
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,89.1,81.7,95.0
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,79.6,71.7,87.8
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,70.4,62.3,77.6
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,73.7,66.7,82.4
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,73.7,65.6,80.8
SAU,Country,Saudi Arabia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,48.4,44.1,54.5
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,30.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,30.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,40.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,40.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,50.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,60.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,50.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,40.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,40.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,40.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,40.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,30.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,0.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,30.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,30.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,40.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,40.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,50.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,60.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,50.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,40.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,40.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,40.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,40.0,,
SAU,Country,Saudi Arabia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,30.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,4.8,3.7,5.8
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,4.2,3.3,5.2
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,5.1,4.0,6.1
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,4.1,3.2,5.0
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,6.0,4.7,7.2
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,6.1,5.0,7.4
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,4.8,3.9,5.7
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,6.9,5.5,8.3
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,5.0,4.0,5.9
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,3.3,2.6,4.0
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,2.8,2.2,3.3
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,2.4,1.8,2.9
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,5.8,4.4,7.3
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,4.8,3.9,6.1
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,4.2,3.4,5.3
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,5.1,4.2,6.4
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,4.1,3.3,5.2
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,6.0,5.0,7.5
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,6.1,5.1,7.5
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,4.8,4.1,6.0
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,6.9,5.8,8.7
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,5.0,4.2,6.2
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,3.3,2.8,4.2
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,2.8,2.3,3.6
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,2.4,1.9,3.1
SDN,Country,Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,5.8,4.6,7.7
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,90.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,80.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,90.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,70.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,110.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,110.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,90.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,130.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,100.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,70.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,60.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,50.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,130.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,90.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,80.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,90.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,70.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,110.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,110.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,90.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,130.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,100.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,70.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,60.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,50.0,,
SDN,Country,Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,130.0,,
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,21.5,19.0,24.6
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,26.3,23.3,30.1
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,31.5,28.0,35.4
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,46.8,41.5,53.0
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,41.2,36.6,45.8
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,53.2,47.5,60.4
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,56.4,50.2,64.3
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,53.3,47.3,60.0
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,62.3,54.9,71.1
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,66.3,58.6,75.5
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,66.0,57.9,75.6
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,66.0,57.7,76.9
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,72.4,62.4,85.5
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,21.5,18.8,24.3
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,26.3,22.9,29.7
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,31.5,28.1,35.4
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,46.8,41.4,52.8
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,41.2,37.1,46.3
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,53.2,46.9,59.6
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,56.4,49.5,63.4
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,53.3,47.3,59.9
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,62.3,54.6,70.6
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,66.3,58.2,74.9
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,66.0,57.6,75.2
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,66.0,56.7,75.6
SEN,Country,Senegal,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,72.4,61.3,84.0
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,720.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,850.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,970.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,1400.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,1100.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,1400.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,1400.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,1200.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,1400.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,1400.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,1400.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,1400.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,1400.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,720.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,850.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,970.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,1400.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,1100.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,1400.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,1400.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,1200.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,1400.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,1400.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,1400.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,1400.0,,
SEN,Country,Senegal,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,1400.0,,
SGP,Country,Singapore,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,20.0,,
SGP,Country,Singapore,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,30.0,,
SGP,Country,Singapore,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,20.0,,
SGP,Country,Singapore,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,20.0,,
SGP,Country,Singapore,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,20.0,,
SGP,Country,Singapore,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,20.0,,
SGP,Country,Singapore,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,20.0,,
SGP,Country,Singapore,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,20.0,,
SGP,Country,Singapore,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,20.0,,
SGP,Country,Singapore,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,10.0,,
SGP,Country,Singapore,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,10.0,,
SGP,Country,Singapore,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,10.0,,
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,34.8,28.8,41.8
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,45.5,38.2,54.9
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,59.5,50.2,71.0
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,51.8,42.6,61.1
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,48.7,41.0,58.1
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,59.2,49.7,69.7
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,59.9,51.1,69.6
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,66.5,56.5,77.6
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,73.3,62.0,85.7
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,67.3,56.6,80.4
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,61.6,51.4,73.3
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,93.1,76.7,95.0
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,68.7,55.8,83.0
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,34.8,29.1,42.2
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,45.5,37.7,54.2
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,59.5,49.8,70.4
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,51.8,43.8,62.8
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,48.7,40.9,57.8
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,59.2,50.3,70.6
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,59.9,51.6,70.3
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,66.5,57.0,78.2
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,73.3,62.6,86.6
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,67.3,56.4,80.0
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,61.6,51.8,74.0
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,93.1,78.1,95.0
SLE,Country,Sierra Leone,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,68.7,56.8,84.5
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,1800.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,2300.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,3000.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,2700.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,2600.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,3200.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,3300.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,3800.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,4300.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,4100.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,4000.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,6100.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,4500.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,1800.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,2300.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,3000.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,2700.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,2600.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,3200.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,3300.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,3800.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,4300.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,4100.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,4000.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,6100.0,,
SLE,Country,Sierra Leone,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,4500.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,38.6,34.3,43.4
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,45.1,39.1,50.9
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,64.5,56.1,72.5
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,73.8,63.7,83.3
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,70.4,61.7,79.9
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,69.3,60.5,78.7
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,65.2,56.2,73.9
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,67.5,58.9,76.4
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,58.1,49.9,66.8
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,67.2,57.7,76.7
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,59.3,49.3,67.4
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,75.6,65.7,86.0
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,77.8,66.1,88.5
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,38.6,34.3,43.4
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,45.1,39.9,52.0
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,64.5,57.4,74.3
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,73.8,65.4,85.5
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,70.4,62.0,80.3
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,69.3,61.0,79.4
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,65.2,57.6,75.7
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,67.5,59.6,77.3
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,58.1,50.5,67.5
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,67.2,58.9,78.3
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,59.3,52.1,71.2
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,75.6,66.5,87.1
SLV,Country,El Salvador,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,77.8,68.4,91.5
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,100.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,120.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,160.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,180.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,170.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,160.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,140.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,130.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,110.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,120.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,100.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,120.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,120.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,100.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,120.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,160.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,180.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,170.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,160.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,140.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,130.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,110.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,120.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,100.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,120.0,,
SLV,Country,El Salvador,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,120.0,,
SOM,Country,Somalia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
SOM,Country,Somalia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,20.0,,
SOM,Country,Somalia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,40.0,,
SOM,Country,Somalia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,20.0,,
SOM,Country,Somalia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,30.0,,
SOM,Country,Somalia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,70.0,,
SOM,Country,Somalia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,80.0,,
SOM,Country,Somalia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,80.0,,
SOM,Country,Somalia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,90.0,,
SOM,Country,Somalia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,100.0,,
SOM,Country,Somalia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,100.0,,
SOM,Country,Somalia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,110.0,,
SOM,Country,Somalia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,120.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,7.3,5.5,9.4
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,9.7,7.2,12.7
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,10.8,8.1,14.3
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,19.5,14.7,25.0
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,18.3,14.3,23.8
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,42.4,33.4,54.2
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,29.3,22.8,37.6
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,62.3,48.9,81.1
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,70.9,55.6,92.5
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,58.1,44.6,74.6
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,59.5,46.3,77.2
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,56.6,43.9,72.7
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,53.1,41.6,69.3
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,7.3,5.6,9.6
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,9.7,7.5,13.1
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,10.8,8.1,14.3
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,19.5,15.1,25.7
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,18.3,14.1,23.4
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,42.4,33.1,53.8
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,29.3,22.9,37.7
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,62.3,47.8,79.3
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,70.9,54.3,90.4
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,58.1,45.3,75.8
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,59.5,45.9,76.5
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,56.6,44.1,72.9
SSD,Country,South Sudan,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,53.1,40.6,67.7
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,670.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,940.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,1100.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,1900.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,1800.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,4000.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,2800.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,5400.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,5500.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,4400.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,4500.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,4200.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,3900.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,670.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,940.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,1100.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,1900.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,1800.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,4000.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,2800.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,5400.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,5500.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,4400.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,4500.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,4200.0,,
SSD,Country,South Sudan,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,3900.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,31.3,24.0,40.2
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,33.0,25.3,41.7
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,43.8,34.5,57.1
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,30.1,24.0,38.8
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,50.0,39.7,66.0
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,54.8,43.5,69.8
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,44.1,35.7,55.8
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,46.9,38.1,60.8
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,48.4,39.0,61.7
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,76.3,62.1,95.0
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,80.4,66.0,95.0
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,83.3,66.4,95.0
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,86.5,68.2,95.0
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,31.3,24.4,40.8
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,33.0,26.1,43.1
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,43.8,33.6,55.7
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,30.1,23.4,37.9
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,50.0,37.9,62.9
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,54.8,43.0,69.0
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,44.1,34.9,54.5
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,46.9,36.1,57.7
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,48.4,38.0,60.0
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,76.3,60.0,93.8
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,80.4,62.5,95.0
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,83.3,65.2,95.0
STP,Country,Sao Tome and Principe,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,86.5,66.2,95.0
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,30.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,30.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,40.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,30.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,40.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,40.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,30.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,30.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,30.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,50.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,50.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,50.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,50.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,30.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,30.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,40.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,30.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,40.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,40.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,30.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,30.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,30.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,50.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,50.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,50.0,,
STP,Country,Sao Tome and Principe,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,50.0,,
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,63.0,51.6,75.9
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,91.5,74.6,95.0
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,88.8,72.2,95.0
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,87.0,69.9,95.0
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,90.8,75.3,95.0
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,81.7,95.0
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,86.4,69.8,95.0
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,76.1,63.4,94.3
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,72.5,59.3,88.7
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,68.8,55.9,83.8
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,71.9,59.0,87.5
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,62.4,50.9,77.0
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,63.0,52.3,76.9
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,91.5,75.8,95.0
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,88.8,73.5,95.0
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,87.0,72.7,95.0
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,90.8,74.4,95.0
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,80.2,95.0
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,86.4,71.6,95.0
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,76.1,61.4,91.3
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,72.5,59.2,88.5
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,68.8,56.5,84.8
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,71.9,59.2,87.7
SUR,Country,Suriname,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,62.4,50.6,76.5
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,80.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,120.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,120.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,120.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,130.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,140.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,120.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,110.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,100.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,100.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,100.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,90.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,80.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,120.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,120.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,120.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,130.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,140.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,120.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,110.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,100.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,100.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,100.0,,
SUR,Country,Suriname,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,90.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,68.7,59.7,73.8
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,85.4,75.8,92.2
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,83.3,73.6,89.5
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,83.8,73.6,90.8
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,76.9,67.5,82.8
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,83.9,74.5,89.8
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,87.3,77.3,93.3
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,80.4,71.2,85.8
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,94.1,82.2,95.0
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,87.8,95.0
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,89.0,77.3,94.8
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,83.6,95.0
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,86.5,95.0
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,68.7,64.0,79.0
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,85.4,79.2,95.0
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,83.3,77.5,94.2
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,83.8,77.4,95.0
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,76.9,71.5,87.7
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,83.9,78.4,94.5
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,87.3,81.6,95.0
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,80.4,75.3,90.9
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,94.1,88.1,95.0
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,93.4,95.0
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,89.0,83.5,95.0
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,90.8,95.0
SWZ,Country,Eswatini,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,93.9,95.0
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,8300.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,10400.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,10200.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,10300.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,9500.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,10200.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,10400.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,9200.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,10300.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,10400.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,8900.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,9100.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,8900.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,8300.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,10400.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,10200.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,10300.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,9500.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,10200.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,10400.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,9200.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,10300.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,10400.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,8900.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,9100.0,,
SWZ,Country,Eswatini,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,8900.0,,
SYR,Country,Syrian Arab Republic,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
SYR,Country,Syrian Arab Republic,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
SYR,Country,Syrian Arab Republic,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
SYR,Country,Syrian Arab Republic,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,0.0,,
SYR,Country,Syrian Arab Republic,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,0.0,,
SYR,Country,Syrian Arab Republic,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,0.0,,
SYR,Country,Syrian Arab Republic,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,0.0,,
SYR,Country,Syrian Arab Republic,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,0.0,,
SYR,Country,Syrian Arab Republic,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,0.0,,
SYR,Country,Syrian Arab Republic,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,0.0,,
SYR,Country,Syrian Arab Republic,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,0.0,,
SYR,Country,Syrian Arab Republic,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,0.0,,
SYR,Country,Syrian Arab Republic,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,0.0,,
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,18.0,14.0,22.7
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,21.6,16.8,26.8
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,29.4,22.9,36.1
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,48.4,36.3,59.8
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,68.4,53.3,84.1
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,53.1,41.7,64.7
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,50.4,39.3,61.8
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,55.0,43.1,67.2
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,64.9,50.0,79.6
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,72.3,55.6,90.2
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,72.0,55.6,91.5
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,73.1,56.5,91.7
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,64.8,49.2,83.4
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,18.0,14.4,23.2
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,21.6,17.4,27.7
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,29.4,23.9,37.6
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,48.4,39.2,64.7
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,68.4,55.6,87.8
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,53.1,43.6,67.6
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,50.4,41.1,64.7
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,55.0,45.0,70.2
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,64.9,52.9,84.2
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,72.3,57.9,94.0
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,72.0,56.6,93.3
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,73.1,58.3,94.6
TCD,Country,Chad,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,64.8,50.4,85.4
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,1600.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,1900.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,2600.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,4300.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,6100.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,4700.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,4400.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,4800.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,5600.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,6200.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,6100.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,6100.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,5400.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,1600.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,1900.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,2600.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,4300.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,6100.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,4700.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,4400.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,4800.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,5600.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,6200.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,6100.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,6100.0,,
TCD,Country,Chad,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,5400.0,,
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,30.9,24.6,38.2
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,64.7,51.6,79.5
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,71.1,57.7,87.5
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,74.6,58.8,91.0
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,77.4,60.7,95.0
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,82.8,66.7,95.0
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,88.6,70.9,95.0
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,72.6,58.1,89.5
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,82.6,65.1,95.0
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,84.2,66.2,95.0
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,73.5,56.7,93.4
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,75.2,57.6,93.8
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,79.3,59.6,95.0
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,30.9,25.0,38.8
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,64.7,52.6,81.1
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,71.1,57.7,87.6
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,74.6,61.1,94.6
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,77.4,62.5,95.0
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,82.8,67.9,95.0
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,88.6,73.2,95.0
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,72.6,58.9,90.8
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,82.6,66.7,95.0
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,84.2,68.2,95.0
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,73.5,57.8,95.0
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,75.2,60.3,95.0
TGO,Country,Togo,West and Central Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,79.3,62.1,95.0
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,2100.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,4200.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,4400.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,4500.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,4500.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,4600.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,4900.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,3900.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,4300.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,4300.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,3600.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,3600.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,3600.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,2100.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,4200.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,4400.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,4500.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,4500.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,4600.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,4900.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,3900.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,4300.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,4300.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,3600.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,3600.0,,
TGO,Country,Togo,West and Central Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,3600.0,,
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,94.2,78.5,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,94.5,77.6,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,94.3,78.3,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,94.0,78.0,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,94.9,79.5,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,80.1,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,95.0,81.7,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,95.0,81.0,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,82.8,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,81.2,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,81.3,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,81.0,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,81.0,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,94.2,80.4,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,94.5,80.9,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,94.3,81.9,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,94.0,80.3,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,94.9,81.8,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,82.7,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,95.0,82.4,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,95.0,83.6,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,84.9,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,83.3,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,84.5,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,83.9,95.0
THA,Country,Thailand,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,83.7,95.0
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,8600.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,8100.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,7300.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,6600.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,6000.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,5400.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,4900.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,4500.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,4100.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,3600.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,3300.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,3000.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,2700.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,8600.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,8100.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,7300.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,6600.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,6000.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,5400.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,4900.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,4500.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,4100.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,3600.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,3300.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,3000.0,,
THA,Country,Thailand,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,2700.0,,
TJK,Country,Tajikistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,40.0,,
TJK,Country,Tajikistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,60.0,,
TJK,Country,Tajikistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,80.0,,
TJK,Country,Tajikistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,100.0,,
TJK,Country,Tajikistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,160.0,,
TJK,Country,Tajikistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,170.0,,
TJK,Country,Tajikistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,180.0,,
TJK,Country,Tajikistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,160.0,,
TJK,Country,Tajikistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,220.0,,
TJK,Country,Tajikistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,190.0,,
TJK,Country,Tajikistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,210.0,,
TJK,Country,Tajikistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,220.0,,
TJK,Country,Tajikistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,260.0,,
TLS,Country,Timor-Leste,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,0.0,,
TLS,Country,Timor-Leste,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,0.0,,
TLS,Country,Timor-Leste,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,0.0,,
TLS,Country,Timor-Leste,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,0.0,,
TLS,Country,Timor-Leste,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,10.0,,
TLS,Country,Timor-Leste,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,10.0,,
TLS,Country,Timor-Leste,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,20.0,,
TLS,Country,Timor-Leste,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,10.0,,
TLS,Country,Timor-Leste,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,20.0,,
TLS,Country,Timor-Leste,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,10.0,,
TLS,Country,Timor-Leste,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,10.0,,
TLS,Country,Timor-Leste,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,20.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,66.4,56.4,76.4
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,85.2,73.3,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,91.8,80.7,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,70.9,63.2,80.5
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,64.4,57.0,73.7
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,58.5,51.3,65.8
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,83.8,72.8,94.4
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,84.3,73.6,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,91.0,77.6,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,90.6,76.5,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,83.5,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,86.3,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,91.7,69.0,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,66.4,57.7,78.2
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,85.2,75.3,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,91.8,80.0,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,70.9,62.4,79.5
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,64.4,56.3,72.8
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,58.5,52.1,66.9
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,83.8,74.5,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,84.3,73.9,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,91.0,77.6,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,90.6,77.9,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,83.2,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,89.1,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,91.7,73.0,95.0
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,180.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,210.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,210.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,150.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,130.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,110.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,140.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,110.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,110.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,120.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,120.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,120.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,100.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,180.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,210.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,210.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,150.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,130.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,110.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,140.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,110.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,110.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,120.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,120.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,120.0,,
TTO,Country,Trinidad and Tobago,Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,100.0,,
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,8.8,6.2,13.2
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,10.1,6.9,14.5
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,9.5,6.5,14.4
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,12.0,8.4,18.2
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,25.7,18.1,38.2
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,16.5,11.5,24.2
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,11.9,8.3,17.6
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,11.0,7.6,16.5
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,12.0,8.6,18.2
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,17.6,12.4,25.4
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,27.8,19.5,39.9
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,30.8,21.9,44.4
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,40.2,28.2,57.5
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,8.8,5.8,12.3
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,10.1,7.0,14.8
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,9.5,6.3,13.8
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,12.0,7.9,17.1
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,25.7,17.3,36.5
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,16.5,11.3,23.7
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,11.9,8.1,17.1
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,11.0,7.4,16.0
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,12.0,8.0,16.9
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,17.6,12.2,25.0
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,27.8,19.4,39.5
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,30.8,21.4,43.4
TUN,Country,Tunisia,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,40.2,28.1,57.3
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,10.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,10.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,10.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,10.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,30.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,20.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,10.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,10.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,10.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,20.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,30.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,30.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,40.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,10.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,10.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,10.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,10.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,30.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,20.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,10.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,10.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,10.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,20.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,30.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,30.0,,
TUN,Country,Tunisia,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,40.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,60.2,49.9,66.6
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,77.5,65.7,88.5
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,95.0,91.8,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,95.0,85.4,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,93.6,77.7,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,87.7,74.2,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,83.3,70.7,91.8
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,91.8,78.0,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,93.7,77.8,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,91.2,76.7,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,79.2,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,89.0,73.9,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,91.6,74.8,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,60.2,54.4,72.6
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,77.5,67.8,91.5
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,95.0,95.0,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,95.0,91.7,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,93.6,83.3,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,87.7,78.9,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,83.3,75.6,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,91.8,82.1,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,93.7,85.6,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,91.2,81.9,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,85.4,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,89.0,80.3,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,91.6,81.6,95.0
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,40900.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,53000.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,74000.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,74200.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,71100.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,68700.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,66700.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,74700.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,76500.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,74000.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,76700.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,68900.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,68200.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,40900.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,53000.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,74000.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,74200.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,71100.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,68700.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,66700.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,74700.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,76500.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,74000.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,76700.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,68900.0,,
TZA,Country,United Republic of Tanzania,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,68200.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,35.2,30.0,39.1
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,58.6,50.1,65.5
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,93.4,81.7,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,95.0,86.3,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,95.0,95.0,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,95.0,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,95.0,91.1,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,95.0,85.8,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,87.2,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,89.9,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,85.3,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,86.3,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,84.1,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,35.2,31.7,41.3
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,58.6,52.5,68.5
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,93.4,84.5,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,95.0,93.0,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,95.0,95.0,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,95.0,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,95.0,95.0,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,95.0,91.8,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,94.3,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,95.0,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,94.0,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,92.7,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,89.6,95.0
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,28600.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,48200.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,78200.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,88300.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,113000.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,116000.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,96000.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,92300.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,94100.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,94500.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,90900.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,88100.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,83400.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,28600.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,48200.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,78200.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,88300.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,113000.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,116000.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,96000.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,92300.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,94100.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,94500.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,90900.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,88100.0,,
UGA,Country,Uganda,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,83400.0,,
UKR,Country,Ukraine,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,3300.0,,
UKR,Country,Ukraine,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,3600.0,,
UKR,Country,Ukraine,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,3600.0,,
UKR,Country,Ukraine,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,3500.0,,
UKR,Country,Ukraine,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,3400.0,,
UKR,Country,Ukraine,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,3100.0,,
UKR,Country,Ukraine,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,2900.0,,
UKR,Country,Ukraine,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,2700.0,,
UKR,Country,Ukraine,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,2500.0,,
UKR,Country,Ukraine,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,2300.0,,
UKR,Country,Ukraine,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,2200.0,,
UKR,Country,Ukraine,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,2100.0,,
UKR,Country,Ukraine,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,1800.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,24.0,19.6,29.3
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,24.8,20.2,30.3
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,27.9,22.7,34.1
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,34.2,27.9,41.8
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,43.9,35.7,53.6
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,46.6,38.0,57.0
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,50.6,41.2,61.8
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,51.1,41.7,62.5
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,54.1,44.1,66.0
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,55.3,45.1,67.6
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,50.5,41.2,61.7
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,49.9,40.7,61.0
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,56.8,46.3,69.4
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,24.0,19.7,29.5
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,24.8,20.3,30.5
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,27.9,22.8,34.2
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,34.2,28.0,42.0
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,43.9,35.9,53.8
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,46.6,38.2,57.2
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,50.6,41.4,62.0
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,51.1,41.8,62.7
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,54.1,44.2,66.3
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,55.3,45.3,67.9
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,50.5,41.3,62.0
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,49.9,40.8,61.2
UNAAP,Region,UNAIDS - Asia Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,56.8,46.5,69.7
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,16900.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,17100.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,19100.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,22800.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,29000.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,30000.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,32800.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,32400.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,33400.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,33600.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,29300.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,27900.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,31100.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,16900.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,17100.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,19100.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,22800.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,29000.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,30000.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,32800.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,32400.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,33400.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,33600.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,29300.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,27900.0,,
UNAAP,Region,UNAIDS - Asia Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,31100.0,,
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,44.9,36.7,52.5
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,66.8,54.6,78.0
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,83.3,68.1,95.0
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,83.4,68.2,95.0
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,76.9,62.9,89.8
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,74.4,60.9,87.0
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,71.3,58.3,83.3
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,73.4,60.0,85.8
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,77.1,63.0,90.1
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,74.5,60.9,87.1
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,61.9,50.7,72.4
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,64.7,52.9,75.6
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,64.6,52.8,75.5
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,44.9,38.5,55.0
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,66.8,57.1,81.6
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,83.3,71.2,95.0
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,83.4,71.4,95.0
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,76.9,65.8,94.0
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,74.4,63.7,91.0
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,71.3,61.0,87.1
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,73.4,62.8,89.7
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,77.1,66.0,94.3
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,74.5,63.7,91.1
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,61.9,53.0,75.7
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,64.7,55.3,79.1
UNACAR,Region,UNAIDS - Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,64.6,55.3,79.0
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,4100.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,6000.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,7300.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,7200.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,6600.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,6400.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,6100.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,6300.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,6700.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,6600.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,5600.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,5900.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,5900.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,4100.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,6000.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,7300.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,7200.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,6600.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,6400.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,6100.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,6300.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,6700.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,6600.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,5600.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,5900.0,,
UNACAR,Region,UNAIDS - Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,5900.0,,
UNAEECA,Region,UNAIDS - Eastern Europe and Central Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,15100.0,,
UNAEECA,Region,UNAIDS - Eastern Europe and Central Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,16400.0,,
UNAEECA,Region,UNAIDS - Eastern Europe and Central Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,16000.0,,
UNAEECA,Region,UNAIDS - Eastern Europe and Central Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,15600.0,,
UNAEECA,Region,UNAIDS - Eastern Europe and Central Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,18400.0,,
UNAEECA,Region,UNAIDS - Eastern Europe and Central Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,19200.0,,
UNAEECA,Region,UNAIDS - Eastern Europe and Central Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,19700.0,,
UNAEECA,Region,UNAIDS - Eastern Europe and Central Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,19900.0,,
UNAEECA,Region,UNAIDS - Eastern Europe and Central Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,21400.0,,
UNAEECA,Region,UNAIDS - Eastern Europe and Central Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,21600.0,,
UNAEECA,Region,UNAIDS - Eastern Europe and Central Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,23800.0,,
UNAEECA,Region,UNAIDS - Eastern Europe and Central Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,23800.0,,
UNAEECA,Region,UNAIDS - Eastern Europe and Central Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,23200.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,54.8,41.9,65.6
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,67.1,51.4,80.5
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,80.0,61.2,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,85.0,65.1,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,89.6,68.6,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,90.7,69.4,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,88.0,67.4,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,90.0,68.9,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,92.8,71.0,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,94.6,72.4,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,94.7,72.5,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,94.2,72.1,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,93.0,71.2,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,54.8,45.7,71.5
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,67.1,56.0,87.7
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,80.0,66.7,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,85.0,70.9,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,89.6,74.8,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,90.7,75.6,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,88.0,73.5,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,90.0,75.1,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,92.8,77.4,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,94.6,78.9,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,94.7,79.0,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,94.2,78.6,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,93.0,77.6,95.0
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,523000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,641000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,770000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,826000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,872000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,877000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,841000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,855000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,868000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,868000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,846000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,816000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,775000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,523000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,641000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,770000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,826000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,872000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,877000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,841000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,855000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,868000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,868000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,846000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,816000.0,,
UNAESA,Region,UNAIDS - Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,775000.0,,
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,39.2,33.9,44.4
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,42.4,36.7,48.0
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,45.8,39.6,51.8
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,49.6,42.9,56.1
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,52.6,45.6,59.6
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,54.8,47.4,62.1
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,55.8,48.3,63.2
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,60.7,52.6,68.7
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,63.9,55.4,72.4
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,66.8,57.8,75.6
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,56.8,49.2,64.3
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,59.4,51.4,67.3
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,63.8,55.2,72.2
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,39.2,34.6,45.3
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,42.4,37.5,49.0
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,45.8,40.5,52.9
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,49.6,43.8,57.3
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,52.6,46.5,60.8
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,54.8,48.4,63.3
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,55.8,49.3,64.4
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,60.7,53.6,70.1
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,63.9,56.5,73.9
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,66.8,59.0,77.1
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,56.8,50.2,65.6
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,59.4,52.5,68.7
UNALA,Region,UNAIDS - Latin America,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,63.8,56.4,73.7
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,11200.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,12000.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,12900.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,13800.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,14500.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,14900.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,15100.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,16200.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,16800.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,17300.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,14500.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,15100.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,16100.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,11200.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,12000.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,12900.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,13800.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,14500.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,14900.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,15100.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,16200.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,16800.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,17300.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,14500.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,15100.0,,
UNALA,Region,UNAIDS - Latin America,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,16100.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,9.3,7.6,11.2
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,10.2,8.3,12.3
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,12.5,10.2,15.1
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,13.8,11.2,16.6
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,13.8,11.3,16.6
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,14.2,11.6,17.1
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,18.3,14.9,22.0
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,19.3,15.7,23.2
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,20.3,16.6,24.5
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,21.2,17.3,25.6
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,19.0,15.5,22.9
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,19.0,15.5,22.9
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,22.1,18.0,26.6
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,9.3,7.7,11.4
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,10.2,8.5,12.5
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,12.5,10.4,15.3
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,13.8,11.4,16.9
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,13.8,11.5,16.9
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,14.2,11.8,17.4
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,18.3,15.2,22.4
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,19.3,16.0,23.6
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,20.3,16.9,24.9
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,21.2,17.6,26.0
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,19.0,15.8,23.3
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,19.0,15.8,23.3
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,22.1,18.3,27.1
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,440.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,480.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,590.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,650.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,660.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,690.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,890.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,960.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,1000.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,1100.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,970.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,980.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,1100.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,440.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,480.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,590.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,650.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,660.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,690.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,890.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,960.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,1000.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,1100.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,970.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,980.0,,
UNAMENA,Region,UNAIDS - Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,1100.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,28.9,22.7,35.1
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,34.5,27.1,41.9
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,39.6,31.1,48.0
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,48.7,38.2,59.0
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,54.3,42.7,65.9
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,57.0,44.8,69.2
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,60.7,47.7,73.6
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,58.2,45.7,70.6
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,55.5,43.6,67.3
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,56.8,44.6,68.9
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,54.7,43.0,66.4
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,56.5,44.4,68.6
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,53.1,41.7,64.4
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,28.9,23.8,36.8
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,34.5,28.5,43.9
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,39.6,32.6,50.3
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,48.7,40.1,61.9
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,54.3,44.8,69.2
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,57.0,47.0,72.5
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,60.7,50.0,77.2
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,58.2,47.9,74.0
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,55.5,45.7,70.6
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,56.8,46.8,72.3
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,54.7,45.1,69.7
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,56.5,46.6,71.9
UNAWCA,Region,UNAIDS - West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,53.1,43.7,67.5
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,82600.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,97600.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,111000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,135000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,149000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,155000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,162000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,154000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,145000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,146000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,139000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,142000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,130000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,82600.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,97600.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,111000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,135000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,149000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,155000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,162000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,154000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,145000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,146000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,139000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,142000.0,,
UNAWCA,Region,UNAIDS - West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,130000.0,,
UNAWCENA,Region,UNAIDS - Western and Central Europe and North America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,9300.0,,
UNAWCENA,Region,UNAIDS - Western and Central Europe and North America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,9400.0,,
UNAWCENA,Region,UNAIDS - Western and Central Europe and North America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,9500.0,,
UNAWCENA,Region,UNAIDS - Western and Central Europe and North America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,9400.0,,
UNAWCENA,Region,UNAIDS - Western and Central Europe and North America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,9200.0,,
UNAWCENA,Region,UNAIDS - Western and Central Europe and North America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,9100.0,,
UNAWCENA,Region,UNAIDS - Western and Central Europe and North America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,8900.0,,
UNAWCENA,Region,UNAIDS - Western and Central Europe and North America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,8400.0,,
UNAWCENA,Region,UNAIDS - Western and Central Europe and North America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,8000.0,,
UNAWCENA,Region,UNAIDS - Western and Central Europe and North America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,7800.0,,
UNAWCENA,Region,UNAIDS - Western and Central Europe and North America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,7300.0,,
UNAWCENA,Region,UNAIDS - Western and Central Europe and North America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,7100.0,,
UNAWCENA,Region,UNAIDS - Western and Central Europe and North America,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,6900.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,12.7,10.7,14.8
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,22.8,20.0,25.6
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,83.6,73.0,95.0
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,80.3,69.1,92.0
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,74.5,64.9,86.5
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,76.8,66.9,87.6
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,73.3,63.5,82.4
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,53.8,46.7,62.1
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,60.0,52.4,67.0
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,60.6,53.3,69.2
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,57.7,49.9,65.9
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,65.3,56.8,74.4
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,67.2,58.4,76.9
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,12.7,10.9,15.2
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,22.8,20.3,26.0
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,83.6,72.7,95.0
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,80.3,70.1,93.4
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,74.5,64.3,85.6
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,76.8,67.4,88.2
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,73.3,65.2,84.6
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,53.8,46.6,61.9
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,60.0,53.8,68.8
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,60.6,53.1,68.9
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,57.7,50.6,66.8
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,65.3,57.3,75.1
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,67.2,58.7,77.4
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,50.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,120.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,530.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,580.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,540.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,520.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,550.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,450.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,540.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,580.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,580.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,660.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,710.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,50.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,120.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,530.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,580.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,540.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,520.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,550.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,450.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,540.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,580.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,580.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,660.0,,
UZB,Country,Uzbekistan,Eastern Europe and Central Asia,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,710.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,9.1,7.9,10.6
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,10.1,8.9,11.5
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,13.2,11.4,15.0
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,16.2,14.2,18.6
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,20.8,18.3,24.3
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,20.7,18.1,23.8
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,20.9,18.3,23.6
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,17.3,14.8,19.8
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,19.1,16.6,21.6
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,13.7,12.0,15.7
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,17.3,14.8,19.8
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,21.7,18.8,25.1
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,37.3,32.0,43.2
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,9.1,7.8,10.5
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,10.1,8.9,11.5
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,13.2,11.5,15.2
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,16.2,14.0,18.5
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,20.8,17.9,23.7
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,20.7,18.0,23.7
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,20.9,18.4,23.8
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,17.3,15.2,20.2
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,19.1,16.9,22.0
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,13.7,12.1,15.8
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,17.3,15.1,20.3
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,21.7,18.7,25.0
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,37.3,32.2,43.5
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,300.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,310.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,380.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,440.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,540.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,510.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,500.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,400.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,410.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,270.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,330.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,420.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,730.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,300.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,310.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,380.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,440.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,540.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,510.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,500.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,400.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,410.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,270.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,330.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,420.0,,
VEN,Country,Venezuela (Bolivarian Republic of),Latin America and Caribbean,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,730.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,52.1,43.2,61.9
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,44.5,36.2,52.0
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,46.0,39.6,52.8
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,42.0,35.4,48.9
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,58.5,49.3,67.1
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,62.5,53.0,72.0
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,72.0,61.4,84.0
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,79.6,68.3,91.5
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,83.3,70.7,94.7
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,94.1,81.8,95.0
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,82.0,95.0
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,83.7,70.7,95.0
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,76.8,64.7,87.5
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,52.1,43.9,62.8
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,44.5,38.0,54.5
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,46.0,40.0,53.3
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,42.0,36.0,49.8
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,58.5,50.9,69.4
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,62.5,54.3,73.8
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,72.0,61.8,84.5
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,79.6,69.3,92.7
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,83.3,73.3,95.0
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,94.1,81.3,95.0
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,83.6,95.0
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,83.7,71.7,95.0
VNM,Country,Viet Nam,East Asia and Pacific,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,76.8,67.3,91.0
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,1400.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,1200.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,1300.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,1200.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,1600.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,1700.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,1900.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,2000.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,1900.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,2100.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,2000.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,1600.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,1300.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,1400.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,1200.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,1300.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,1200.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,1600.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,1700.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,1900.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,2000.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,1900.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,2100.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,2000.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,1600.0,,
VNM,Country,Viet Nam,East Asia and Pacific,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,1300.0,,
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,8.6,7.9,9.5
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,2.9,2.6,3.2
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,5.4,4.9,6.0
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,6.8,6.1,7.4
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,5.0,4.6,5.4
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,2.4,2.2,2.6
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,1.0,1.0,1.0
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,3.2,2.9,3.4
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,3.1,2.8,3.3
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,6.9,6.2,7.5
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,3.4,3.1,3.7
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,7.1,6.4,7.6
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,23.8,21.8,25.8
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,8.6,7.8,9.4
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,2.9,2.6,3.1
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,5.4,5.0,6.0
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,6.8,6.2,7.5
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,5.0,4.5,5.4
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,2.4,2.2,2.6
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,1.0,1.0,1.0
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,3.2,2.9,3.4
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,3.1,2.8,3.4
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,6.9,6.3,7.6
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,3.4,3.1,3.7
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,7.1,6.5,7.8
YEM,Country,Yemen,Middle East and North Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,23.8,21.9,25.9
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,0.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,20.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,20.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,60.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,0.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,20.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,10.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,20.0,,
YEM,Country,Yemen,Middle East and North Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,60.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,85.0,52.9,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,88.8,56.5,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,95.0,60.9,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,95.0,64.6,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,95.0,63.3,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,61.6,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,95.0,62.8,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,95.0,60.2,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,61.7,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,63.4,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,63.3,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,63.1,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,61.3,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,85.0,61.2,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,88.8,62.6,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,95.0,70.0,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,95.0,74.4,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,95.0,73.7,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,95.0,71.3,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,95.0,72.3,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,95.0,72.6,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,95.0,71.9,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,95.0,72.8,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,95.0,73.1,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,95.0,74.6,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,95.0,72.6,95.0
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,266000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,273000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,300000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,324000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,319000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,307000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,298000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,296000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,295000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,291000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,286000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,278000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,257000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,266000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,273000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,300000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,324000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,319000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,307000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,298000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,296000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,295000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,291000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,286000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,278000.0,,
ZAF,Country,South Africa,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,257000.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,62.4,54.2,67.6
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,65.5,57.1,72.7
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,70.0,61.6,76.1
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,79.2,67.9,86.8
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,85.4,74.5,94.0
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,79.8,70.4,86.9
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,84.3,74.2,90.7
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,90.4,78.8,95.0
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,86.0,74.7,93.1
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,90.5,78.9,95.0
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,92.1,78.5,95.0
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,91.0,77.5,95.0
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,90.6,75.8,95.0
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,62.4,57.6,71.8
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,65.5,59.1,75.2
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,70.0,64.4,79.6
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,79.2,72.2,92.4
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,85.4,77.6,95.0
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,79.8,73.3,90.5
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,84.3,78.3,95.0
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,90.4,82.6,95.0
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,86.0,79.4,95.0
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,90.5,82.9,95.0
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,92.1,85.0,95.0
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,91.0,83.7,95.0
ZMB,Country,Zambia,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,90.6,83.3,95.0
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,35500.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,37600.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,40100.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,45300.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,48700.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,45400.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,47800.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,51000.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,48400.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,50400.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,50400.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,48200.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,46100.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,35500.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,37600.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,40100.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,45300.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,48700.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,45400.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,47800.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,51000.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,48400.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,50400.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,50400.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,48200.0,,
ZMB,Country,Zambia,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,46100.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,29.8,23.3,34.4
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,48.3,37.7,55.7
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,75.3,58.7,86.7
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,74.6,58.2,85.9
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,81.1,63.3,93.4
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,81.1,63.2,93.4
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,86.7,67.6,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,90.5,70.6,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,92.5,72.2,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,93.7,73.1,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,87.9,68.5,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,85.4,66.6,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,84.6,66.0,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,29.8,25.9,38.2
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,48.3,42.0,62.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,75.3,65.3,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,74.6,64.7,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,81.1,70.4,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,81.1,70.3,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,86.7,75.2,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,90.5,78.5,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,92.5,80.3,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,93.7,81.3,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,87.9,76.2,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,85.4,74.1,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,84.6,73.4,95.0
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,21100.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,35900.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,55800.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,54800.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,58700.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,57400.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,59600.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,60600.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,59600.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,57600.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,51200.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,47000.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,43900.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,21100.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,35900.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,55800.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,54800.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,58700.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,57400.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,59600.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,60600.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,59600.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,57600.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,51200.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,47000.0,,
ZWE,Country,Zimbabwe,Eastern and Southern Africa,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,43900.0,,
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,45.7,36.4,54.6
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,45.3,36.1,54.1
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,45.4,36.2,54.3
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,45.6,36.3,54.5
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,48.4,38.5,57.8
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,50.1,39.9,59.8
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,49.3,39.3,59.0
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,50.9,40.6,60.9
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,54.6,43.4,65.2
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,56.1,44.6,67.0
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,55.5,44.2,66.3
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,45.0,35.8,53.8
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,48.1,38.3,57.5
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,45.7,38.3,57.5
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,45.3,37.9,56.9
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,45.4,38.0,57.1
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,45.6,38.2,57.3
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,48.4,40.5,60.8
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,50.1,41.9,62.9
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,49.3,41.3,62.0
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,50.9,42.6,64.0
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,54.6,45.7,68.6
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,56.1,46.9,70.4
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,55.5,46.4,69.7
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,45.0,37.7,56.6
regionEAP,Region,East Asia and Pacific,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,48.1,40.3,60.5
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,16700.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,16800.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,17200.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,17100.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,18200.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,18500.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,18300.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,18800.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,19100.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,19100.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,17800.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,13800.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,14400.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,16700.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,16800.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,17200.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,17100.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,18200.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,18500.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,18300.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,18800.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,19100.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,19100.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,17800.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,13800.0,,
regionEAP,Region,East Asia and Pacific,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,14400.0,,
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,54.5,41.7,65.3
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,66.8,51.1,80.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,79.5,60.8,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,84.5,64.7,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,89.2,68.3,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,90.2,69.1,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,87.7,67.2,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,89.7,68.7,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,92.4,70.7,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,94.2,72.1,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,94.4,72.3,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,93.9,71.9,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,92.7,71.0,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,54.5,45.5,71.2
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,66.8,55.7,87.2
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,79.5,66.3,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,84.5,70.5,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,89.2,74.4,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,90.2,75.3,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,87.7,73.2,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,89.7,74.8,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,92.4,77.1,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,94.2,78.6,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,94.4,78.8,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,93.9,78.3,95.0
regionESA,Region,Eastern and Southern Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,92.7,77.3,95.0
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,526000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,644000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,773000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,829000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,875000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,881000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,846000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,859000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,872000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,871000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,851000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,821000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,779000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,526000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,644000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,773000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,829000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,875000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,881000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,846000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,859000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,872000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,871000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,851000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,821000.0,,
regionESA,Region,Eastern and Southern Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,779000.0,,
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,40.6,34.6,46.3
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,48.3,41.2,55.1
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,54.7,46.7,62.4
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,57.6,49.1,65.7
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,58.4,49.8,66.7
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,59.5,50.8,67.9
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,59.5,50.8,67.9
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,63.8,54.4,72.8
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,67.2,57.4,76.7
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,68.7,58.7,78.5
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,58.1,49.6,66.4
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,60.8,51.9,69.4
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,64.0,54.6,73.1
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,40.6,35.5,47.6
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,48.3,42.3,56.6
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,54.7,47.9,64.1
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,57.6,50.4,67.5
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,58.4,51.2,68.4
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,59.5,52.1,69.7
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,59.5,52.1,69.7
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,63.8,55.9,74.7
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,67.2,58.9,78.8
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,68.7,60.2,80.6
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,58.1,50.9,68.1
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,60.8,53.3,71.3
regionLAC,Region,Latin America and Caribbean,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,64.0,56.1,75.0
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,15200.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,18000.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,20200.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,21000.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,21100.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,21300.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,21200.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,22500.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,23500.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,23900.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,20200.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,21000.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,22000.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,15200.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,18000.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,20200.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,21000.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,21100.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,21300.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,21200.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,22500.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,23500.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,23900.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,20200.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,21000.0,,
regionLAC,Region,Latin America and Caribbean,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,22000.0,,
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,18.7,16.2,22.1
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,19.5,16.9,23.1
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,24.1,20.9,28.5
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,28.2,24.5,33.3
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,25.8,22.4,30.5
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,22.4,19.4,26.4
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,31.6,27.4,37.3
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,33.0,28.6,38.9
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,36.3,31.5,42.9
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,39.3,34.1,46.4
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,34.9,30.3,41.2
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,34.6,30.0,40.8
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,37.7,32.6,44.4
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,18.7,15.9,21.6
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,19.5,16.5,22.5
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,24.1,20.5,27.9
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,28.2,23.9,32.5
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,25.8,21.9,29.8
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,22.4,19.0,25.8
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,31.6,26.7,36.4
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,33.0,27.9,38.0
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,36.3,30.8,41.9
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,39.3,33.3,45.3
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,34.9,29.6,40.3
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,34.6,29.3,39.9
regionMENA,Region,Middle East and North Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,37.7,31.9,43.4
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,400.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,440.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,560.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,690.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,660.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,600.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,860.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,920.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,1000.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,1100.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,970.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,970.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,1100.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,400.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,440.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,560.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,690.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,660.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,600.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,860.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,920.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,1000.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,1100.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,970.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,970.0,,
regionMENA,Region,Middle East and North Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,1100.0,,
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,1.0,1.0,1.0
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,1.0,1.0,1.0
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,5.9,4.9,7.3
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,19.4,16.2,24.1
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,38.0,31.7,47.2
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,42.3,35.3,52.5
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,52.5,43.8,65.2
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,51.6,43.1,64.1
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,53.5,44.7,66.5
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,54.6,45.5,67.8
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,44.3,37.0,55.0
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,56.0,46.8,69.6
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,67.6,56.4,83.9
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,1.0,1.0,1.0
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,1.0,1.0,1.0
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,5.9,4.7,7.0
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,19.4,15.6,23.3
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,38.0,30.6,45.5
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,42.3,34.0,50.6
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,52.5,42.3,62.9
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,51.6,41.6,61.9
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,53.5,43.1,64.1
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,54.6,43.9,65.4
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,44.3,35.7,53.1
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,56.0,45.1,67.1
regionSA,Region,South Asia,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,67.6,54.4,81.0
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,130.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,200.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,1800.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,5500.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,10700.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,11300.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,14300.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,13500.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,14200.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,14300.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,11300.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,13900.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,16600.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,130.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,200.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,1800.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,5500.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,10700.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,11300.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,14300.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,13500.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,14200.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,14300.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,11300.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,13900.0,,
regionSA,Region,South Asia,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,16600.0,,
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,48.7,37.5,58.5
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,59.6,45.9,71.6
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,70.7,54.4,85.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,76.8,59.1,92.3
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,81.7,62.9,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,83.1,64.0,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,81.9,63.0,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,82.9,63.9,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,84.5,65.0,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,86.1,66.3,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,85.6,65.9,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,85.5,65.8,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,83.7,64.5,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,48.7,40.5,63.2
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,59.6,49.6,77.4
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,70.7,58.8,91.8
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,76.8,63.9,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,81.7,68.0,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,83.1,69.1,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,81.9,68.1,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,82.9,69.0,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,84.5,70.3,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,86.1,71.7,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,85.6,71.2,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,85.5,71.1,95.0
regionSSA,Region,Sub-Saharan Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,83.7,69.7,95.0
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,606000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,739000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,881000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,961000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,1021000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,1032000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,1004000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,1008000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,1013000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,1014000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,986000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,958000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,906000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,606000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,739000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,881000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,961000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,1021000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,1032000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,1004000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,1008000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,1013000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,1014000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,986000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,958000.0,,
regionSSA,Region,Sub-Saharan Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,906000.0,,
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2010,28.7,22.5,34.8
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2011,34.4,27.0,41.8
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2012,39.5,31.0,48.0
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2013,48.7,38.2,59.1
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2014,54.4,42.7,66.0
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2015,56.9,44.7,69.1
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2016,60.4,47.4,73.3
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2017,57.9,45.5,70.4
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2018,55.3,43.4,67.1
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2019,56.7,44.6,68.9
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2020,53.9,42.3,65.4
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2021,55.8,43.8,67.7
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring and UNAIDS 2023 estimates,2022,52.5,41.2,63.7
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2010,28.7,23.6,36.5
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2011,34.4,28.3,43.8
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2012,39.5,32.5,50.3
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2013,48.7,40.1,62.0
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2014,54.4,44.8,69.2
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2015,56.9,46.8,72.4
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2016,60.4,49.7,76.9
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2017,57.9,47.7,73.8
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2018,55.3,45.5,70.4
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2019,56.7,46.7,72.2
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2020,53.9,44.4,68.6
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2021,55.8,45.9,71.0
regionWCA,Region,West and Central Africa,,Per cent of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring and UNAIDS 2023 estimates,2022,52.5,43.2,66.8
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2010,80000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2011,95000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2012,108000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2013,132000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2014,146000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2015,151000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2016,158000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2017,150000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2018,141000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2019,143000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2020,134000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2021,138000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),Global AIDS Monitoring,2022,127000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2010,80000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2011,95000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2012,108000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2013,132000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2014,146000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2015,151000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2016,158000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2017,150000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2018,141000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2019,143000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2020,134000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2021,138000.0,,
regionWCA,Region,West and Central Africa,,Reported number of pregnant women living with HIV receiving lifelong ART,Global AIDS Monitoring,2022,127000.0,,
